

A population-based phenome-wide association study of cardiac and aortic structure and function

Wenjia Bai^{1,2,*}, Hideaki Suzuki^{2,11,12}, Jian Huang^{3,9}, Catherine Francis⁴, Shuo Wang¹, Giacomo Tarroni^{5,10}, Florian Guitton¹, Nay Aung⁶, Kenneth Fung⁶, Steffen E. Petersen⁶, Stefan K. Piechnik⁷, Stefan Neubauer⁷, Evangelos Evangelou^{3,13}, Abbas Dehghan^{3,9}, Declan P. O'Regan⁸, Martin R. Wilkins⁴, Yike Guo¹, Paul M. Matthews^{2,9,**}, and Daniel Rueckert^{5,**}

¹Data Science Institute, Imperial College London, London, UK

²Department of Brain Sciences, Imperial College London, London, UK

³MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK

⁴National Heart and Lung Institute, Imperial College London, London, UK

⁵Biomedical Image Analysis Group, Department of Computing, Imperial College London, London, UK

⁶NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, UK

⁷NIHR Oxford Biomedical Research Centre, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

⁸MRC London Institute of Medical Sciences, Imperial College London, London, UK

⁹UK Dementia Research Institute, Imperial College London, London, UK

¹⁰CitAI Research Centre, Department of Computer Science, City University of London, London, UK

¹¹Department of Cardiovascular Medicine, Tohoku University Hospital, Sendai, Japan

¹²Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan

¹³Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece

*First and corresponding author: w.bai@imperial.ac.uk

**Joint senior authors: p.matthews@imperial.ac.uk, d.rueckert@imperial.ac.uk

ABSTRACT

Differences in cardiac and aortic structure and function are associated with cardiovascular diseases and a wide range of other types of disease. Here we analyzed cardiovascular magnetic resonance images from a population-based study, the UK Biobank, using an automated machine learning-based analysis pipeline. We report a comprehensive range of structural and functional phenotypes for the heart and aorta across 26,893 participants and explore how these phenotypes vary according to sex, age and major cardiovascular risk factors. We extended this analysis with a phenome-wide association study, in which we tested for correlations of a wide range of non-imaging phenotypes of the participants with imaging phenotypes. We further explored the associations of imaging phenotypes with early-life factors, mental health and cognitive function using both observational analysis and Mendelian randomization. Our study illustrates how population-based cardiac and aortic imaging phenotypes can be used to better define cardiovascular disease risks as well as heart-brain health interactions, highlighting new opportunities for studying disease mechanisms and developing image-based biomarkers.

Cardiac and aortic structure and function are associated with cardiovascular diseases (CVDs)^{1,2} and a wide range of other types of disease³⁻⁶. Quantitative phenotypes derived from cardiovascular magnetic resonance (CMR) images enable us to assess cardiac and aortic structure and function in a non-invasive way and provide important biomarkers for the determination of pathological states in CVDs. For example, the left ventricular ejection fraction (LVEF) is an important clinical biomarker for the diagnosis and treatment of heart failure¹. The left ventricular myocardial mass (LVM) is widely used for classifying hypertrophy and predicting risks of cardiovascular events⁷. Although CMR imaging phenotypes clearly play an important role in disease research and diagnosis, extracting these phenotypes demand significant involvement of experienced image analysts. This has become a limiting factor for applying CMR in large-scale studies and exploiting imaging phenotypes at a population level.

Large-scale imaging studies potentially provide a wealth of information for investigating disease risk factors and discovering early-stage image-based biomarkers. Recent large-scale imaging studies collecting CMR images include the Framingham Heart

Study (offspring cohort: 1,114 subjects)⁸, MESA (5,004 subjects)⁹, DETERMINE (655 subjects)¹⁰, Dallas Heart Project (2,921 subjects)¹¹ and UK Digital Heart Project (~2,000 subjects)¹², to name a few. They illustrated the potential informativeness of CMR in large-scale studies, but lacked the power to explore a wide range of individual phenotypes simultaneously.

UK Biobank is a population-based prospective study for investigating risk factors of common adult diseases in middle and old age¹³⁻¹⁶. It recruited 500,000 women and men initially aged 40-69 years old between 2006-10 for long-term follow-up, from whom extensive sociodemographic, life-style and health-related information were collected serially along with a range of physical measurements and a growing range of genetic and biomarker data. Currently, UK Biobank is in the process of acquiring comprehensive multi-modal images of different organ systems from 100,000 participants using a highly standardised protocol, including magnetic resonance (MR) scans of the heart, brain and abdomen, ultrasound scans of carotid arteries, whole body dual-energy X-ray absorptiometry (DXA) scan of bones and joints, retinal photographs and optical coherence tomography (OCT) images¹⁴. These will add additional imaging phenotypes for understanding the determinants of diseases.

Deriving quantitative imaging phenotypes at this scale forms a major challenge. Recently, an image analysis pipeline has been developed for UK Biobank brain MR images, which generates ~4,350 imaging phenotypes of brain structure and function for 10,000 subjects¹⁷. The derived brain imaging phenotypes, along with the breadth of life-style and health information collected by UK Biobank, provide a valuable resource for studying the influence of ageing, progression of neuropathology and identifying early-stage image-based biomarkers for diseases¹⁸. An initial genome-wide association study (GWAS) has been performed¹⁹, which identified 148 clusters of associations between single nucleotide polymorphisms (SNPs) and brain imaging phenotypes that replicate at $p < 0.05$, providing insights into the genetic architecture relevant to the brain.

Here we present cardiac and aortic structural and functional imaging phenotypes for 26,893 subjects and demonstrate association studies enabled by these imaging phenotypes at a population level. The phenotypes were derived from UK Biobank CMR images using an automated machine learning-based analysis pipeline, built upon previously proposed cardiac and aortic image segmentation methods using convolutional neural networks^{20,21}. The pipeline evaluates comprehensive imaging phenotypes for the heart and aorta, including global phenotypes of the four cardiac chambers and two aortic sections: the left ventricle (LV), right ventricle (RV), left atrium (LA), right atrium (RA), ascending aorta (AAo) and descending aorta (DAo), as well as regional phenotypes of the LV myocardial wall thickness and strain. We report associations of the cardiac and aortic imaging phenotypes with sex, age and traditional cardiovascular risk factors. We then conducted a large, population-based phenome-wide association study to relate the cardiac and aortic phenotypes to non-imaging phenotypes. We discovered a wide range of highly significant associations with life style, early-life factors, mental health and cognitive function of the participants.

Results

Image phenotyping

Figure 1 summarises the image analysis steps performed on short-axis, long-axis and aortic cine images (see detail in Methods). In total, 82 quantitative imaging phenotypes characterising the structure and function of the heart and aorta (Table 1) were generated for each subject. After running the analysis pipeline and performing quality control (Supplementary Table 1), imaging phenotypes were available for 26,893 subjects. Supplementary Table 2 describes the basic participant characteristics of the population. Supplementary Tables 3-6 report the summary statistics of the derived imaging phenotypes.

Associations with sex and age

We investigated imaging phenotypes which describe cardiac and aortic size (mass, volume or area) and change (ejection fraction or distensibility) during a cardiac cycle. Two or three imaging phenotypes were selected for each of the six anatomical structures, including the LV myocardial mass (LVM), LV end-diastolic volume (LVEDV), LV ejection fraction (LVEF), RV end-diastolic volume (RVEDV), RV ejection fraction (RVEF), LA maximum volume (LAV max), LA ejection fraction (LAEF), RA maximum volume (RAV max), RA ejection fraction (RAEF), AAo maximum area, AAo distensibility, DAo maximum area and DAo distensibility.

We first characterised the associations of these phenotypes with sex and age in the population. Subjects with self-reported CVDs were excluded to mitigate the impact of established cardiac conditions on imaging phenotypes. As the majority of the subjects were Caucasian, we excluded other ethnicities to mitigate the impact of ethnicity. After these exclusions, 23,415 subjects were used with available sex and age information. Multiple linear regression models were built, using each imaging phenotype as the dependent variable and sex and age as independent variables. An interaction term sex * age was included for LVM, LVEDV, RVEDV, RAEF, AAo distensibility and DAo distensibility, where it led to a model of better fit (one-sided F-test, $p < 0.05$).

Figure 2 and Supplementary Table 7 report the regression results. Overall, myocardial mass (LVM: $\beta = 53.0$, $p = 3 \times 10^{-218}$), cardiac chamber volumes (LVEDV: $\beta = 53.1$, $p = 2.9 \times 10^{-74}$; RVEDV: $\beta = 71.1$, $p = 7.7 \times 10^{-116}$; LAV max: $\beta = 10.6$, $p = 2.6 \times 10^{-297}$; RAV max: $\beta = 22.7$, $p = 10^{-324}$) and aortic cross-sectional areas (AAo max area: $\beta = 143.9$, $p = 10^{-324}$; DAo max area: $\beta = 104.9$, $p = 10^{-324}$) were greater for men than for women. Men consistently had lower cardiac chamber

ejection fractions (LVEF: $\beta = -3.2$, $p = 10^{-324}$; RVEF: $\beta = -4.1$, $p = 10^{-324}$; LAEF: $\beta = -0.9$, $p = 1.7 \times 10^{-15}$; RAEF: $\beta = -8.9$, $p = 1.4 \times 10^{-19}$) than women.

In this cross-sectional study, ageing was associated with reduced myocardial mass and cardiac chamber volumes (LVM: $\beta = -1.0$, $p = 2.2 \times 10^{-12}$; LVEDV: $\beta = -5.9$, $p = 2.5 \times 10^{-136}$; RVEDV: $\beta = -6.1$, $p = 4.7 \times 10^{-130}$; LAV max: $\beta = -2.0$, $p = 9.1 \times 10^{-44}$; RAV max: $\beta = -1.0$, $p = 1.7 \times 10^{-9}$), increased aortic areas (AAo max area: $\beta = 29.3$, $p = 6.1 \times 10^{-146}$; DAo max area: $\beta = 20.8$, $p = 10^{-324}$) and reduced aortic distensibilities (AAo disten.: $\beta = -0.7$, $p = 10^{-324}$; DAo disten.: $\beta = -0.8$, $p = 10^{-324}$). We found that women had greater aortic distensibilities than men between 40 to 50 years old (Figure 2). However, there was a strong sex and age interaction (AAo disten.: $\beta = 0.1$, $p = 8.4 \times 10^{-14}$; DAo disten.: $\beta = 0.1$, $p = 10^{-11}$). Aortic distensibilities decreased more quickly with age for women than for men. LVM, LVEDV, RVEDV and RAEF also exhibited strong sex and age interactions. Myocardial mass and ventricular volumes decreased more quickly with age for men than for women (LVM: $\beta = -2.4$, $p = 5.6 \times 10^{-36}$; LVEDV: $\beta = -1.5$, $p = 8.6 \times 10^{-6}$; RVEDV: $\beta = -2.6$, $p = 4.6 \times 10^{-13}$).

Associations with traditional cardiovascular risk factors

We explored the associations of cardiac and aortic imaging phenotypes with demographics (sex, age, sex * age), anthropometrics (weight, height) and cardiovascular risk factors²², including systolic blood pressure (SBP), diastolic blood pressure (DBP), current smoking status, alcohol intake, vigorous physical activity (PA) frequency, high cholesterol and diabetes. Sex, current smoking status, high cholesterol and diabetes are binary variables. The others are continuous variables.

Supplementary Table 8 reports the regression coefficients and p-values for these factors. Figure 3 plots the regression coefficients with 95% confidence intervals. As expected, higher weight or height was associated with greater cardiac chamber volumes and aortic areas (p ranges from 10^{-324} to 4.1×10^{-15} , apart from weight with RAV max). Higher SBP was associated with greater myocardial mass (LVM: $\beta = 4.8$, $p = 10^{-324}$), greater ventricular volumes (LVEDV: $\beta = 5.8$, $p = 2.4 \times 10^{-130}$; RVEDV: $\beta = 3.0$, $p = 4.8 \times 10^{-32}$), greater ventricular ejection fractions (LVEF: $\beta = 0.9$, $p = 4.9 \times 10^{-49}$; RVEF: $\beta = 1.6$, $p = 1.4 \times 10^{-161}$) and lower aortic distensibilities (AAo disten.: $\beta = -0.2$, $p = 1.1 \times 10^{-41}$; DAo disten.: $\beta = -0.3$, $p = 2.9 \times 10^{-53}$). Smoking, higher alcohol intake and more frequent vigorous PA were associated with greater LVM (p ranges from 6.4×10^{-132} to 6.7×10^{-8}). Smoking and vigorous PA both were associated with lower left ventricular ejection fraction (p ranges from 1.1×10^{-4} to 0.037). Diabetes was associated with lower myocardial mass, lower cardiac chamber volumes, lower ejection fractions and aortic areas (p ranges from 3.4×10^{-34} to 0.025, apart from RAEF).

Associations with clinical outcomes

We also explored the associations of cardiac and aortic imaging phenotypes with 12 categories of common diseases, defined by self-reported disease code (Supplementary Table 9). Figure 4 and Supplementary Table 10 report the odds ratios (ORs) and p-values of each imaging phenotype as a risk factor for a common disease as the outcome in logistic regression. Greater LVM was associated with higher risk of hypertension ($OR = 1.66$, $p = 3 \times 10^{-84}$) and cardiac disease ($OR = 1.41$, $p = 1.8 \times 10^{-19}$). Greater cardiac chamber volumes were associated with higher risk of cardiac disease (p ranges from 1.5×10^{-63} to 0.008) and with lower risk of diabetes, asthma, COPD and bronchitis (p ranges from 1.3×10^{-37} to 0.004, apart from LVEDV with asthma). Greater cardiac chamber ejection fractions were associated with lower risk of cardiac disease and diabetes (p ranges from 2.3×10^{-107} to 0.028, apart from RAEF with diabetes). Greater aortic areas were associated with higher risk of hypertension (p ranges from 4.6×10^{-55} to 1.3×10^{-19}) and lower risk of diabetes (p ranges from 3.7×10^{-17} to 1.8×10^{-10}). Greater aortic distensibilities were associated with lower risk of hypertension and high cholesterol (p ranges from 6.6×10^{-30} to 0.022).

Phenome-wide association study

We performed a phenome-wide association study (PheWAS) to explore the correlations between imaging phenotypes and 11 categories of non-imaging phenotypes of the participants. The non-imaging phenotypes include primary demographics, early-life factors, education and employment, diet, alcohol, smoking, physical activity, physical measures, self-reported medical conditions, mental health and cognitive function. Figure 5a shows the Manhattan plot of the univariate correlation p-values (two-sided) between imaging phenotypes and non-imaging phenotypes and Figure 5b shows the correlation coefficients. Univariate correlations were performed between $M = 82$ imaging phenotypes and $N = 555$ non-imaging phenotypes for $M \times N = 45,510$ times, with 2,617 correlations reaching the Bonferroni threshold for multiple comparisons ($p_{\text{Bonf}} = 1.1 \times 10^{-6}$ for $\alpha = 0.05$) and 6,481 correlations reaching the false discovery rate (FDR) threshold ($p_{\text{FDR}} = 0.007$ for $\alpha = 0.05$).

Supplementary Table 11 lists the five most significant PheWAS associations for each anatomical structure. Higher SBP, more frequent PA and lower pulse rate were most consistently associated with larger cardiac chamber volumes. Overall health rating was associated with lower cardiac chamber volumes. Higher birth weight, whole body fat mass and hip circumference were associated with larger aortic areas.

Figure 5a also highlights associations between cardiac imaging phenotypes and mental health and cognitive performance phenotypes. Supplementary Table 12 presents five most significant PheWAS associations with mental health phenotypes. Risk taking and neuroticism score were significantly associated with cardiac and aortic phenotypes. Supplementary Table 13 reports

the most significant associations with cognitive performance, assessed as fluid intelligence score, response time or number of correct trials completed in cognitive tests.

Further exploring associations with birth weight, mental health and cognitive performance

Following the mass univariate characterisation of associations using PheWAS, we selected several novel and most strongly associated non-imaging phenotypes and performed multiple linear regressions to further investigate their associations with cardiac and aortic structure and function. We adjusted for sex, age, sex * age, weight, height, SBP, DBP, current smoking status, alcohol intake, vigorous PA frequency, high cholesterol, diabetes and added the non-imaging phenotypes of interest as additional independent variables.

Birth weight: Early-life influences and birth weight are associated with later-life cardiovascular disease risk²³. A previous, smaller population study concluded that these can be attributed to influences on general somatic growth²⁴. We investigated this further. Extended Data Figure 1 shows the conditional plots of imaging phenotypes against birth weight and Supplementary Table 14 reports detailed regression coefficients and p-values. Even with control for current weight and height as covariates, birth weight was still significantly associated with myocardial mass and cardiac chamber volumes (LVM: $\beta = 0.5$, $p = 1.4 \times 10^{-5}$; LVEDV: $\beta = 1.0$, $p = 7.5 \times 10^{-7}$; RVEDV: $\beta = 1.8$, $p = 7.4 \times 10^{-15}$; LAV max: $\beta = -0.7$, $p = 4.3 \times 10^{-4}$; RAV max: $\beta = 1.7$, $p = 2.2 \times 10^{-14}$) and in particular with aortic areas. Higher birth weight was associated with greater aortic areas (AAo max area: $\beta = 20.2$, $p = 10^{-40}$; DAo max area: $\beta = 7.1$, $p = 3.2 \times 10^{-26}$) and lower aortic distensibilities (AAo disten.: $\beta = -0.04$, $p = 8.8 \times 10^{-4}$; DAo disten.: $\beta = -0.1$, $p = 5.5 \times 10^{-4}$).

Risk taking and neuroticism: Symptoms potentially related to the heart and CVDs have an increased prevalence amongst people with depression and suggestive associations with other psychological states or traits, such as anxiety, stress or anger²⁵. Here we extend these observations with evidence for more general associations of affective and psychological traits with cardiac and aortic structure and function (Supplementary Table 15). Risk taking behaviour was associated with greater LVM ($\beta = 1.0$, $p = 4.4 \times 10^{-6}$) and lower ejection fractions (LVEF: $\beta = -0.3$, $p = 0.004$; RVEF: $\beta = -0.5$, $p = 1.6 \times 10^{-7}$; LAEF: $\beta = -0.5$, $p = 0.001$; RAEF: $\beta = -0.8$, $p = 5.3 \times 10^{-7}$). Higher neuroticism score was associated with lower cardiac chamber volumes (LVEDV: $\beta = -0.6$, $p = 0.002$; RVEDV: $\beta = -1.0$, $p = 9.8 \times 10^{-7}$; LAV max: $\beta = -0.4$, $p = 0.023$; RAV max: $\beta = -0.7$, $p = 3.7 \times 10^{-4}$).

Fluid intelligence: Subclinical population variation in cardiac haemodynamics has been associated with measures of processing speed and executive function in an Icelandic population²⁶, although both the association and its potential mechanisms remain controversial²⁷. With the greater statistical power afforded by this large population study, we have found similar and much stronger associations in a UK population (Supplementary Table 16). Higher fluid intelligence score was strongly associated with greater LVM ($\beta = 0.8$, $p = 1.8 \times 10^{-18}$) and greater cardiac chamber volumes (LVEDV: $\beta = 1.1$, $p = 3.3 \times 10^{-10}$; RVEDV: $\beta = 2.0$, $p = 2 \times 10^{-26}$; RAV max: $\beta = 1.6$, $p = 1.9 \times 10^{-20}$). We further performed a mediation analysis (Extended Data Figure 2), regressing fluid intelligence score against the LVM, using the brain volume as a mediator and adjusting for the same covariates. In this model, higher LVM was strongly associated with greater brain volume ($\beta = 0.189$, $p = 1.3 \times 10^{-53}$), which was associated with higher fluid intelligence score ($\beta = 0.330$, $p = 3.7 \times 10^{-49}$). Approximately one-fourth (26%) of the association between LVM and fluid intelligence score was mediated by brain volume.

Mendelian randomisation

By leveraging the SNPs associated with risk factors as instrumental variables and the genetic data from UK Biobank, we performed two-sample Mendelian randomisation analysis to investigate the relationships between risk factors and cardiac or aortic imaging phenotypes. Five risk factors, which have publicly available genetic association statistics that are needed for Mendelian randomisation, were investigated (Supplementary Tables 17). Three Mendelian methods were used, including inverse-variance weighting (IVW), weighted median (WM) and MR-Egger. Comparisons of heterogeneity statistics²⁸ suggested that IVW and MR-Egger fitted equally well in most of the Mendelian randomisation analyses with the ratio statistic Q_R being close to 1. Supplementary Table 18 compares the effect sizes and p-values of Mendelian randomisation (detailed results in Supplementary Table 19) to observational analysis results. Higher SBP was associated with greater LVM (IVW: $\beta = 4.8$, $p = 0.006$; WM: $\beta = 4.6$, $p = 0.044$) and lower AAO distensibility (IVW: $\beta = -0.3$, $p = 0.042$; WM: $\beta = -0.4$, $p = 0.048$) with the same effect direction as conventional observational associations. Diabetes was associated with lower AAO max area (IVW: $\beta = -12.0$, $p = 0.003$) and with the same effect direction as the observational association. However, findings for SBP and diabetes were not significant after Bonferroni correction for multiple testing ($p_{\text{Bonf}} = 1.4 \times 10^{-3}$ for $\alpha = 0.05$). Birth weight was associated with LVM, LVEDV, RVEDV and AAO max area (IVW and WM: p ranges from $p = 6.2 \times 10^{-8}$ to 0.049) and with consistent effect directions to those seen with observational analyses. The findings for birth weight using the IVW method sustained after adjustment for multiple testing and also with $Q_R > 0.99$. The effect directions of risk taking and fluid intelligence on imaging phenotypes were mostly consistent with observational associations, although the effects were not statistically significant. The MR-Egger pleiotropy test was only significant for the association between birth weight and AAO distensibility ($p = 0.014$).

Discussion

This study makes four major contributions. First, we presented quantitative phenotypes for six anatomical structures of the heart and aorta on a population-level CMR study, which were extracted using an automated machine learning-based analysis pipeline. We have returned the derived imaging phenotypes from the 26,893 subjects included in this study to UK Biobank to be made available for use by other researchers. A data visualisation website was built (<https://heartvis.doc.ic.ac.uk>), which allows researchers to explore the associations between imaging phenotypes and non-imaging phenotypes. We have shared the image analysis pipeline (https://github.com/baiwenjia/ukbb_cardiac), which we anticipate will be a generally valuable resource for CMR image analysis. Second, we demonstrated the potential informativeness of quantitative cardiac and aortic imaging phenotypes, which enabled both targeted association studies and a large-scale PheWAS. Third, based on novel observations in the PheWAS, we reported significant associations of cardiac and aortic phenotypes with a wide range of participant phenotypes, including birth weight, mental health and cognitive performance measures, illustrating the utility of generating these phenotypes even from a relatively healthy population when acquired at such a novel scale. Finally, we investigated the effects of these non-imaging phenotypes on imaging phenotypes using Mendelian randomisation and provided further evidence supporting the meaningfulness of the observational associations.

Using the imaging phenotypes, we characterised age-related changes in the heart and aorta for women and men. In this cross-sectional study, ageing was strongly associated with lower volumes of all the four cardiac chambers and with higher ejection fractions. Compared to cardiac chamber volumes and ejection fractions, aortic distensibilities were even more sensitive to age. For example, the mean distensibility of the ascending aorta in our population was substantially lower at 70 years old ($1.3 \times 10^{-3} \text{ mmHg}^{-1}$) than at 50 years old ($3.1 \times 10^{-3} \text{ mmHg}^{-1}$), consistent with the previous finding of an age-related tendency to increased arterial stiffness^{29,30}. Women showed a steeper decline of aortic distensibility with age compared to men. Some study suggested that this may be a consequence of physiological changes after menopause³⁰.

Our study substantially extends findings in²² with association tests over a wider range of structural and functional phenotypes. We showed strong relationships of cardiac and aortic imaging phenotypes with SBP, smoking, alcohol intake, PA and diabetes, all of which are well described risk factors for cardiovascular diseases²². Although the percentage of current smokers is relatively low in this UK Biobank imaging subcohort (3.7%) compared to the full UK Biobank cohort (10.5%)³¹ or the general UK population³², we still found a relatively large effect size for smoking, highlighting its association with subclinical differences in cardiac structure and function³³. In addition, due to the large sample size that we have, small signals of influence on cardiac and aortic anatomy and function are able to be detected. For example, although the effect sizes were relatively small, alcohol intake was highly significantly associated with greater myocardial mass, cardiac chamber volumes and aortic areas, which could not be established in an earlier, smaller population study²².

Additional associations between cardiac or aortic imaging phenotypes and prevalent diseases suggested their potentials for predicting the risks of diseases. Greater left ventricular mass or cavity volumes were associated with increased risk of cardiac diseases³⁴. We also found that greater right ventricular volume was associated with increased risks for lung diseases, including asthma, COPD and bronchitis. This is probably due to the physiological interaction between the heart and the lung, consistent with previous findings^{35,36}. Aortic areas and distensibilities, which play important roles in the haemodynamics of the circulatory system³⁷, were highly associated with the risk of hypertension.

The PheWAS analysis demonstrated that cardiac and aortic imaging phenotypes were significantly correlated with a wide range of non-imaging phenotypes of the participants (Supplementary Tables 20 and 21). PheWAS is a data-driven way to generate new hypotheses regarding developmental, life-style, clinical and environmental influences on disease risks through the discovery of their associations with population variation in cardiac and aortic anatomy and function. Particularly interesting were associations with early-life development, traits related to mental health and cognitive function. The large population allowed the identification of highly significant associations of aortic structure with birth weight independent of the general anthropometric measures such as adult height and weight³⁸. We found associations between higher birth weight and greater aortic area, the diameter of which is a possible predictor for all cause mortality and incident cardiovascular events³⁹.

The PheWAS also provided novel data for generating hypotheses relating cardiovascular function to mental health. We found that risk-taking behaviour was significantly associated with greater left ventricular myocardial mass and lower ventricular and atrial ejection fractions. This could be explained by common co-morbid behaviours such as smoking, drug and alcohol abuse^{40,41}, which are independently associated with cardiovascular diseases^{42,43}. Alternatively, neurogenic factors may contribute directly to cardiac remodelling⁴⁴. Associations of risk taking with brain structure and function have been described⁴⁵.

Our exploration of fluid intelligence score associations supports conclusions of an earlier, smaller study²⁶, suggesting relationships between cardiovascular and cognitive function. Many studies have already demonstrated the importance of cardiovascular function in cognition and cognitive diseases^{6,46}. This may be a consequence of shared risk factors between dementia and cardiovascular diseases, such as smoking, hypertension, high cholesterol and diabetes⁴⁷ or direct consequences of impaired cardiovascular function on the brain⁴⁸. Our mediation analysis demonstrated a positive association between heart and brain structure, the latter of which was positively associated with general cognitive ability⁴⁹.

The Mendelian randomisation analysis provided further evidence for the associations between non-imaging phenotypes and imaging phenotypes. Perhaps most interesting was the potential causal relationship discovered between birth weight and cardiac and aortic structures even in mid-later ages. This substantially extends earlier findings that heart size at birth has subtle but significant and persistent effects on cardiac structure into adulthood⁵⁰. While the positive association between SBP and left ventricular mass is consistent with a previous interventional study⁵¹, it raises questions about the best interpretation of a more recent interventional study showing that intensive blood pressure (BP) control and standard BP control reduced left ventricular mass to a similar extent⁵². There was a negative association between diabetes and aortic area and distensibility, an observation that is useful for understanding observations such as the negative relationship of aortic distensibility to all cause mortality⁵³.

However, there are several limitations to our analysis approach and observations. First, the central component of the image analysis pipeline, the convolutional neural network (CNN), was trained using UK Biobank images^{20,21}. It is possible to adapt the pipeline to images scanned on different systems or using different protocols, if training data is available for retraining or fine-tuning the network⁵⁴. To apply the pipeline to images with completely unknown characteristics, however, the neural network is likely to produce less accurate segmentations. In machine learning, this problem is referred to as transfer learning or domain adaptation and machine learning methods that can reliably address this problem still remain elusive⁵⁵. Second, the image analysis pipeline is automated. However, at this point, quality control for the image segmentation, was still performed manually. A future methodological extension is to develop and incorporate accurate and automated quality control to reduce the need for this manual intervention. Third, our image analysis pipeline focuses on a limited range of short-axis, long-axis and aortic cine images, which broadly characterise the cardiac and aortic structure and function. UK Biobank also collects tagged MR, aortic valve flow and T1 map images, the analysis of which will provide additional imaging phenotypes for the heart and aorta. Fourth, while Mendelian randomisation analysis may provide support for certain potential causal relationships, more reliable evidence needs to be provided by interventional research⁵⁶. In the two-sample Mendelian randomisation analysis, the genetic associations of SBP, birth weight and risk taking were obtained from meta-analyses on both UK Biobank cohort and other cohorts (Supplementary Table 17), as findings excluding UK Biobank cohort were not available. This may introduce bias due to the overlap between the samples for risk factor GWAS and the samples for outcome (imaging phenotype) associations⁵⁷. The summed proportion of variance in risk factors explained by all independent SNPs ($r^2 < 0.1$) ranged from 0.25% (risk taking), 0.44% (SBP) to 10.78% (fluid intelligence) (Supplementary Tables 22-26). The relatively lower proportions of variance explained for risk taking and SBP may indicate bias due to the overlapping sample. However, since only a UK Biobank imaging subcohort ($n = 22,229$) was used for outcome associations, the overlap with the SBP ($n = 1,006,863$), birth weight ($n=298,142$) or risk taking GWAS cohort ($n = 466,571$) and the resulting bias may be presumed to be small. For the other risk factors used for Mendelian randomisation, the genetic associations were obtained from cohorts other than UK Biobank and thus without overlapping samples. Finally, the UK Biobank population is a relatively healthy cohort compared to the general UK population¹⁴. The extent to which observations are generalisable to populations with other ethnic mixes or with different frequencies of co-morbid diseases will need to be explored. The current imaging study focuses on observational associations on a cross-sectional dataset from a specific population, which may limit its generalisability for estimation of associations in other populations or making causal inferences. However, a re-imaging project for a subset of 10,000 UK Biobank subjects has just begun, which will increase its value for longitudinal studies.

In summary, we have developed and applied novel analytical methods to generate quantitative and clinically relevant phenotypes of the heart and aorta for 26,893 CMR images from the ongoing UK Biobank study. We have defined 2,617 significant associations between imaging phenotypes and non-imaging phenotypes of the participants, which provides a proof of principle for the use of quantitative imaging phenotypes for more precisely describing relationships between risk factors and cardiovascular diseases. Our findings provide novel insights into the influence of early-life factors and diabetes on cardiac and aortic structure and function, as well as the interaction between heart and cognitive phenotypes. We also demonstrate that in conjunction with data on genetic determinants of individual susceptibilities to life style or co-disease risks, causal relationships can be better defined using instruments such as Mendelian randomisation and genetic data available from UK Biobank¹⁶. A particular opportunity afforded by UK Biobank is the linkage to the long-term health outcomes of the participants through the National Health Service (NHS) record. In principle, this should enable extensions of investigations from associations to causal models for major later-life disorders. The power for such studies will increase rapidly over time. For example, of the 100,000 imaging participants, it was estimated that approximately 5,600 participants will have myocardial infarction (MI) and coronary death by 2022, rising to 9,400 by 2027 (diabetes: 8,000 rising to 13,600; stroke: 1,800 rising to 4,000; Alzheimer's disease: 1,800 rising to 6,000)¹⁴. The derived imaging phenotypes, together with participant health information and other phenotype and genotype data, will provide a valuable resource for extension of studies on genetic architecture relevant to the heart, discovering risk factors and early-stage biomarkers for a variety of diseases and for new understanding in emerging areas of interest, such as the relationship between late-life heart and brain health.

Acknowledgements

We would like to thank He Gao, Deborah Schneider-Luftman, Timothy J.W. Dawes and Arinbjorn Kolbeinnsson for fruitful discussion. This research was conducted using the UK Biobank Resource under Application Number 18545, using methods developed under Application Number 18545 or 2964. Images were reproduced by kind permission of UK Biobank. We wish to thank all UK Biobank participants and staff. This work is supported by the SmartHeart EPSRC Programme Grant (EP/P001009/1) and the Imperial BHF Centre of Excellence Grant (RE/18/4/34215). H.S. is supported by a research fellowship from the Uehara Memorial Foundation and the Grants-in-Aid program from the Japan Society for the Promotion of Science (20K07776). S.E.P. acknowledges support from the NIHR Barts Biomedical Research Centre and S.E.P. has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 825903 (euCanShare project). S.E.P., S.N. and S.K.P. acknowledge the British Heart Foundation for funding the manual analysis to create a cardiovascular magnetic resonance imaging reference standard for the UK Biobank imaging resource in 5000 CMR scans (PG/14/89/31194). A.D. is funded by the Wellcome Trust seed award (206046/Z/17/Z). D.P.O. is supported by the Medical Research Council (MC-A651-53301) and British Heart Foundation (NH/17/1/32725, RG/19/6/34387, RE/18/4/34215). P.M.M. gratefully acknowledges support from the Edmond J. Safra Foundation and Lily Safra, the Imperial College Healthcare Trust Biomedical Research Centre, the EPSRC Centre for Mathematics in Precision Healthcare and the UK Dementia Research Institute.

Author contributions

W.B. developed the analysis pipeline and wrote the manuscript; H.S. performed manual quality control of image segmentations and provided advice on clinical research; J.H. performed Mendelian randomisation; C.F. provided support on genetic data analysis; S.W. developed the data visualisation website; G.T. and Y.G. provided advice and support on the computational methodology; F.G. provided support on data management; H.S., N.A., K.F., S.E.P., S.K.P., S.N., E.E., A.D., D.P.O. and M.R.W. provided advice and support on clinical research; W.B., P.M.M. and D.R. conceived and designed the study. All authors read, contributed to revision and approved the manuscript.

Competing interests statement

S.E.P. acknowledges consultancy fees from Circle Cardiovascular Imaging Inc., Calgary, Alberta, Canada. D.R. acknowledges consultancy fees from Circle Cardiovascular Imaging Inc., Calgary, Alberta, Canada, Heartflow, Redwood City, CA, USA and IXICO PLC, London, UK. P.M.M. acknowledges consultancy fees from Roche, Adelphi Communications, Celgene and Biogen. He has received honoraria or speakers' honoraria from Novartis, Biogen and Roche and has received research or educational funds from Biogen, Novartis, GlaxoSmithKline and Nodthera. He is a member of the Scientific Advisory Board to the Board of Ipsen Pharmaceuticals. The remaining authors declare no competing interests.

References

1. Ponikowski, P. *et al.* 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur. J. Hear. Fail.* **18**, 891–975 (2016).
2. Erbel, R. *et al.* 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. *Eur. Hear. J.* **35**, 2873–2926 (2014).
3. Watz, H. *et al.* Decreasing cardiac chamber sizes and associated heart dysfunction in COPD. *Chest* **138**, 32–38 (2010).
4. Alonso-Gonzalez, R. *et al.* Abnormal lung function in adults with congenital heart disease: Prevalence, relation to cardiac anatomy, and association with survival. *Circulation* **127**, 882–890 (2013).
5. Gansevoort, R. T. *et al.* Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *The Lancet* **382**, 339–352 (2013).
6. de Bruijn, R. F. & Ikram, M. A. Cardiovascular risk factors and future risk of Alzheimer's disease. *BMC Medicine* **12**, 130 (2014).
7. Armstrong, A. C. *et al.* LV mass assessed by echocardiography and CMR, cardiovascular outcomes, and medical practice. *JACC: Cardiovasc. Imaging* **5**, 837–848 (2012).
8. Jefferson, A. L. *et al.* Relation of left ventricular ejection fraction to cognitive aging (from the Framingham Heart Study). *The Am. J. Cardiol.* **108**, 1346–1351 (2011).
9. Bild, D. E. Multi-ethnic study of atherosclerosis: Objectives and design. *Am. J. Epidemiol.* **156**, 871–881 (2002).
10. Kadish, A. H. *et al.* Rationale and design for the defibrillators to reduce risk by magnetic resonance imaging evaluation (DETERMINE) trial. *J. Cardiovasc. Electrophysiol.* **20**, 982–987 (2009).

11. Victor, R. G. *et al.* The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. *The Am. J. Cardiol.* **93**, 1473–1480 (2004).
12. Bello, G. A. *et al.* Deep-learning cardiac motion analysis for human survival prediction. *Nat. Mach. Intell.* **1**, 95–104 (2019).
13. Collins, R. What makes UK Biobank special? *The Lancet* **379**, 1173–1174 (2012).
14. Sudlow, C. *et al.* UK Biobank: An open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLOS Medicine* **12**, e1001779 (2015).
15. Manolio, T. A. UK Biobank debuts as a powerful resource for genomic research. *Nat. Medicine* **24**, 1792–1794 (2018).
16. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).
17. Alfaro-Almagro, F. *et al.* Image processing and quality control for the first 10,000 brain imaging datasets from UK Biobank. *NeuroImage* **166**, 400–424 (2018).
18. Miller, K. L. *et al.* Multimodal population brain imaging in the UK Biobank prospective epidemiological study. *Nat. Neurosci.* **19**, 1523–1536 (2016).
19. Elliott, L. T. *et al.* Genome-wide association studies of brain imaging phenotypes in UK Biobank. *Nature* **562**, 210–216 (2018).
20. Bai, W. *et al.* Automated cardiovascular magnetic resonance image analysis with fully convolutional networks. *J. Cardiovasc. Magn. Reson.* **20**, 65 (2018).
21. Bai, W. *et al.* Recurrent neural networks for aortic image sequence segmentation with sparse annotations. In *International Conference on Medical Image Computing and Computer-Assisted Intervention*, 586–594 (2018).
22. Heckbert, S. R. *et al.* Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging. *J. Am. Coll. Cardiol.* **48**, 2285–2292 (2006).
23. Geelhoed, J. J. M. & Jaddoe, V. W. V. Early influences on cardiovascular and renal development. *Eur. J. Epidemiol.* **25**, 677–692 (2010).
24. Hardy, R., Ghosh, A. K., Deanfield, J., Kuh, D. & Hughes, A. D. Birthweight, childhood growth and left ventricular structure at age 60–64 years in a British birth cohort study. *Int. J. Epidemiol.* 1091–1102 (2016).
25. Chaddha, A., Robinson, E. A., Kline-Rogers, E., Alexandris-Souphis, T. & Rubenfire, M. Mental health and cardiovascular disease. *The Am. J. Medicine* **129**, 1145–1148 (2016).
26. Sabayan, B. *et al.* Cardiac hemodynamics are linked with structural and functional features of brain aging: The age, gene/environment susceptibility (AGES)-Reykjavik Study. *J. Am. Hear. Assoc.* **4** (2015).
27. Friedrich, M. G. Interplay of cardiac and cognitive function: How much do we really understand? *J. Am. Hear. Assoc.* **4** (2015).
28. Bowden, J. *et al.* Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression. *Int. J. Epidemiol.* **47**, 1264–1278 (2018).
29. Redheuil, A. *et al.* Reduced ascending aortic strain and distensibility: Earliest manifestations of vascular aging in humans. *Hypertension* **55**, 319–326 (2010).
30. Nethononda, R. M. *et al.* Gender specific patterns of age-related decline in aortic stiffness: a cardiovascular magnetic resonance study including normal ranges. *J. Cardiovasc. Magn. Reson.* **17**, 20 (2015).
31. Gibson, L. M. *et al.* Factors associated with potentially serious incidental findings and with serious final diagnoses on multi-modal imaging in the UK Biobank Imaging Study: A prospective cohort study. *PLOS ONE* **14**, e0218267 (2019).
32. Fry, A. *et al.* Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. *Am. J. Epidemiol.* **186**, 1026–1034 (2017).
33. Nadruz, W. *et al.* Smoking and cardiac structure and function in the elderly. *Circ. Cardiovasc. Imaging* **9** (2016).
34. Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B. & Castelli, W. P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *New Engl. J. Medicine* **322**, 1561–1566 (1990).
35. Steingrub, J. S., Tidswell, M. & Higgins, T. L. Hemodynamic consequences of heart-lung interactions. *J. Intensive Care Medicine* **18**, 92–99 (2003).
36. Repessé, X., Charron, C. & Vieillard-Baron, A. Acute cor pulmonale in ARDS: Rationale for protecting the right ventricle. *Chest* **147**, 259–265 (2015).

37. Alastruey, J., Xiao, N., Fok, H., Schaeffter, T. & Figueroa, C. A. On the impact of modelling assumptions in multi-scale, subject-specific models of aortic haemodynamics. *J. The Royal Soc. Interface* **13**, 20160073 (2016).
38. Jiang, B., Godfrey, K. M., Martyn, C. N. & Gale, C. R. Birth weight and cardiac structure in children. *Pediatrics* **117**, e257–e261 (2006).
39. Kamimura, D. *et al.* Increased proximal aortic diameter is associated with risk of cardiovascular events and all-cause mortality in blacks the Jackson Heart Study. *J. Am. Hear. Assoc.* **6** (2017).
40. de Haan, L., Egberts, A. & Heerdink, E. The relation between risk-taking behavior and alcohol use in young adults is different for men and women. *Drug Alcohol Dependence* **155**, 222–227 (2015).
41. Kreek, M. J., Nielsen, D. A., Butelman, E. R. & LaForge, K. S. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. *Nat. Neurosci.* **8**, 1450–1457 (2005).
42. Ambrose, J. A. & Barua, R. S. The pathophysiology of cigarette smoking and cardiovascular disease. *J. Am. Coll. Cardiol.* **43**, 1731–1737 (2004).
43. Ronksley, P. E., Brien, S. E., Turner, B. J., Mukamal, K. J. & Ghali, W. A. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. *BMJ* **342**, d671–d671 (2011).
44. Rozanski, A., Blumenthal, J. A. & Kaplan, J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. *Circulation* **99**, 2192–2217 (1999).
45. Strawbridge, R. J. *et al.* Genetics of self-reported risk-taking behaviour, trans-ethnic consistency and relevance to brain gene expression. *Transl. Psychiatry* **8**, 178 (2018).
46. Qiu, C. & Fratiglioni, L. A major role for cardiovascular burden in age-related cognitive decline. *Nat. Rev. Cardiol.* **12**, 267–277 (2015).
47. Gorelick, P. B. *et al.* Vascular contributions to cognitive impairment and dementia. *Stroke* **42**, 2672–2713 (2011).
48. van Buchem, M. A. *et al.* The heart-brain connection: A multidisciplinary approach targeting a missing link in the pathophysiology of vascular cognitive impairment. *J. Alzheimer's Dis.* **42**, S443–S451 (2014).
49. Royle, N. A. *et al.* Estimated maximal and current brain volume predict cognitive ability in old age. *Neurobiol. Aging* **34**, 2726–2733 (2013).
50. Arnott, C. *et al.* Subtle increases in heart size persist into adulthood in growth restricted babies: the Cardiovascular Risk in Young Finns Study. *Open Hear.* **2**, e000265 (2015).
51. Simpson, H. J. *et al.* Left ventricular hypertrophy: reduction of blood pressure already in the normal range further regresses left ventricular mass. *Heart* **96**, 148–152 (2010).
52. Upadhyaya, B. *et al.* Effect of intensive blood pressure reduction on left ventricular mass, structure, function, and fibrosis in the SPRINT-HEART. *Hypertension* **74**, 276–284 (2019).
53. Cruickshank, K. *et al.* Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance. *Circulation* **106**, 2085–2090 (2002).
54. Bhuvu, A. N. *et al.* A multicenter, scan-rescan, human and machine learning CMR study to test generalizability and precision in imaging biomarker analysis. *Circ. Cardiovasc. Imaging* **12** (2019).
55. Marcus, G. Deep learning: A critical appraisal. *arXiv: 1801.00631* (2018).
56. Davies, N. M., Holmes, M. V. & Davey Smith, G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ* k601 (2018).
57. Burgess, S., Davies, N. M. & Thompson, S. G. Bias due to participant overlap in two-sample Mendelian randomization. *Genet. Epidemiol.* **40**, 597–608 (2016).




Figure 1. Automated CMR image analysis pipeline. **a)** LV and RV volumes are derived from short-axis image segmentation (red: LV cavity; green: myocardium; blue: RV cavity). **b, c)** LA and RA volumes are derived from long-axis image segmentation (purple: LA cavity; orange: RA cavity), as illustrated using a 4 chamber view (b) and a 2 chamber view (c). **d)** AAO and DAO cross-sectional areas are derived from aortic image segmentation (red: AAO; green: DAO). **e)** Myocardial wall thickness is measured using the distance between LV endocardial contour (red) and epicardial contour (green). **f)** For measurement of myocardial wall thickness, three short-axis image slices are selected, including a basal slice at 25% of the LV length (the distance from the mitral annular plane to the apex of the LV), a mid-cavity slice at 50% and an apical slice at 75% of the LV length. The endocardial and epicardial contours are divided into 16 AHA segments, which are coded by different colors, as indicated by the color bar. **g)** Motion tracking is performed on short-axis image slices, warping the contours to each time frame across a cardiac cycle. Circumferential and radial strains (color-coded on the contours) are calculated using the change of length of the line segments. **h)** On the long-axis 4 chamber view image, the endocardial and epicardial contours are divided into 6 segments (coded by different colors). **i)** Motion tracking is performed on the long-axis 4 chamber view image. Longitudinal strain is calculated using the change of length of the line segments.




Figure 2. Associations of selected imaging phenotypes with sex and age. Each graph displays a kernel density plot of an imaging phenotype plotted against age, as well as the linear regression lines for the whole population (gray), for women (red) and for men (blue). $n = 23,415$ subjects were included in the analysis. Detailed regression coefficients and association p-values can be found in Supplementary Table 7.




Figure 3. Regression coefficients for cardiac and aortic imaging phenotypes on demographics (blue), anthropometrics (green) and cardiovascular risk factors (red). For continuous variables, the coefficient describes the effect per standard deviation of the variable. For binary variables, the coefficient describes the effect with a change in the variable from 0 to 1. The gray bars denote the 95% confidence interval. n = 19,988 subjects were included in the analysis.




Figure 4. Associations of cardiac and aortic imaging phenotypes with common diseases. (a) Odds ratio for an imaging phenotype as a risk factor for a common disease as the outcome. Sex, age, weight and height were adjusted in a logistic regression analysis. $n = 25,743$ subjects were included in the analysis. (b) The corresponding p-values (two-sided t-test) for odds ratios shown in (a). *: reaching the FDR threshold ($p_{FDR} = 0.017$ for $\alpha = 0.05$); **: reaching the Bonferroni threshold ($p_{Bonf} = 3.2 \times 10^{-4}$ for $\alpha = 0.05$).




Figure 5. Phenome-wide association study. (a) Manhattan plot showing the p-values (two-sided t-test) for correlations between imaging phenotypes and non-imaging phenotypes. The height of each data point denotes the negative logarithm of the univariate correlation p-value between one imaging phenotype and one non-imaging phenotype. The area of the data point denotes the absolute value of the Pearson's correlation coefficient. The colour of the data point denotes the anatomical structure of the imaging phenotype. The Bonferroni threshold for multiple comparisons ($\alpha = 0.05$) is shown as a dashed horizontal line. $n = 26,893$ subjects were included in the analysis. (b) Plot showing the Pearson's correlation coefficients between imaging phenotypes and non-imaging phenotypes. The height of each data point denotes the correlation coefficient and the area denotes the negative logarithm of the p-value (two-sided t-test).

Anatomical structure	Quantitative imaging phenotypes
Left ventricle (LV)	End-diastolic volume, end-systolic volume, stroke volume, ejection fraction, cardiac output, myocardial mass, global and regional myocardial wall thickness at end-diastole, global and regional peak circumferential, radial and longitudinal strains
Right ventricle (RV)	End-diastolic volume, end-systolic volume, stroke volume, ejection fraction
Left atrium (LA)	Maximum volume, minimum volume, stroke volume, ejection fraction
Right atrium (RA)	Maximum volume, minimum volume, stroke volume, ejection fraction
Ascending aorta (AAo)	Maximum area, minimum area, aortic distensibility
Descending aorta (DAo)	Maximum area, minimum area, aortic distensibility

Table 1. Quantitative imaging phenotypes of the heart and aorta, derived from short-axis, long-axis and aortic cine images.

Methods

Data

UK Biobank is an open access resource, open to bona fide scientists undertaking health-related research that is in the public good. Ethical approval is obtained from the North West Research Ethics Committee (REC reference: 11/NW/0382) and written consent is obtained from all participants. The UK Biobank CMR protocol is described in⁵⁸. In brief, CMR images are acquired using clinical wide bore 1.5 Tesla scanners (MAGNETOM Aera, Syngo Platform VD13A, Siemens Healthcare, Erlangen, Germany). The image analysis pipeline consists of several parts, respectively for short-axis, long-axis and aortic cine images, which provide measures for different anatomical structures.

Short-axis image analysis

The LV, myocardium and RV are segmented on short-axis cine images using a fully convolutional network²⁰, which was trained on manual annotations of 3,975 subjects. The LV and RV volumes across a cardiac cycle are derived from segmentation, as illustrated in Figure 1a. The end-diastolic volume (EDV), end-systolic volume (ESV), stroke volume (SV) and ejection fraction (EF) are determined for both ventricles. The LV myocardial mass is calculated from the myocardial volume using a density of 1.05 g/mL. The myocardial wall thickness is measured on each image slice using the distance between endocardial contour and epicardial contour at the end-diastolic (ED) frame, illustrated in Figure 1e. The myocardium is divided into 16 AHA segments according to⁵⁹. The AHA segment model is a standard model recommended by the American Heart Association (AHA), which divides the LV into 16 or 17 segments for assessing regional variations of structure and function. Based on the model, the mean wall thickness for each segment and the global mean wall thickness are calculated.

Motion tracking is performed on short-axis images using non-rigid image registration⁶⁰ between successive time frames, using the MIRTk toolkit. The inter-frame displacement fields are composed to obtain the displacement at frame k with regard to the reference frame, the ED frame or frame 0. To avoid the drift effect due to the accumulation of registration errors⁶¹, motion tracking is performed twice, respectively along the forward direction (tracking starting from frame 0 to frames 1, 2, 3, ...) and backward direction (tracking from frame 0 to frames $T - 1$, $T - 2$, $T - 3$, ..., where T denotes the number of frames per cardiac cycle). The average displacement field is calculated by weighted averaging the forward field and backward field, $u_{0 \rightarrow k}(x) = \frac{T-k}{T} \cdot u_{0 \rightarrow k, forward}(x) + \frac{k}{T} \cdot u_{0 \rightarrow k, backward}(x)$, where $u_{0 \rightarrow k}(x)$ denotes the displacement from frame 0 to frame k at pixel x , and $\frac{T-k}{T}$ and $\frac{k}{T}$ denote the weights for the forward and backward displacement fields. For a frame at the early stage of a cardiac cycle (small k), the forward displacement field will have a higher weight. For a frame at the late stage of a cardiac cycle (k close to T), the backward displacement field will have a higher weight.

Three images slices are used for motion tracking, namely a basal slice at 25% of the LV length (the distance from the mitral annular plane to the apex of the LV), a mid-cavity slice at 50% and an apical slice at 75% of the LV length, according to^{62,63}. The myocardial contours on the three slices are divided into AHA 16 segments, illustrated in Figure 1f. Based on the displacement field from motion tracking, myocardial contours at the ED frame are warped onto each time frame of the cardiac cycle, illustrated in Figure 1g. Circumferential and radial strains are calculated for each time frame based on the change of length for each line segment according to⁶⁴, using the equation $E_{dir} = \frac{\Delta L_{dir}}{L_{dir}}$, where dir denotes the direction, L_{dir} denotes the length of a line segment along this direction and ΔL_{dir} denotes its change. The peak strain for each segment and the global peak strain are calculated.

Long-axis image analysis

The LA and RA are segmented on long-axis 4-chamber (4Ch) view cine images using neural networks²⁰, illustrated in Figure 1b. The LA and RA 4Ch areas and longitudinal diameters are determined from the segmentation. The LA is also segmented on long-axis 2-chamber view (2Ch), illustrated in Figure 1c. The LA 2Ch area and longitudinal diameter are also determined. The LA volume is calculated using the biplane area-length formula $V = \frac{8}{3\pi} \cdot \frac{A_{2Ch} \cdot A_{4Ch}}{L}$, where A_{2Ch} and A_{4Ch} denotes the atrial area on the 2Ch and 4Ch view, L denotes the longitudinal diameter averaged across two views^{65,66}. The RA volume is calculated using $V = \frac{8}{3\pi} \cdot \frac{A_{4Ch}^2}{L}$. The maximum, minimum volumes and the ejection fraction are determined for both atria.

Motion tracking is performed on long-axis 4Ch view images, using the same approach as short-axis image motion tracking. The longitudinal strain is calculated from 4Ch view motion tracking results. The myocardial contour is divided into 6 segments, basal septal (1), basal lateral (2), mid septal (3), mid lateral (4), apical septal (5) and apical lateral (6), illustrated in Figure 1h. The peak strain for each segment and the global peak strain are calculated.

Aortic image analysis

The AAO and DAAo are segmented on aortic cine images using a spatio-temporal neural network²¹, illustrated in Figure 1d. The maximum and minimum cross-sectional areas, A_{max} and A_{min} , are derived from the segmentation. The aortic distensibility is calculated by $D = \frac{A_{max} - A_{min}}{A_{min} \cdot (P_{max} - P_{min})}$, where P_{max} denotes the central systolic blood pressure and P_{min} denotes the central diastolic

blood pressure. The central blood pressure is calculated from the brachial blood pressure using Vicorder (Skidmore Medical, Bristol, UK) by applying a previously described brachial-to-aortic transfer function⁵⁸.

Quality control

All image segmentations are manually quality controlled by an experienced cardiologist. The segmentation screenshots for short-axis, long-axis and aortic images at ED and ES frames are visually inspected. Bad segmentations, images with insufficient coverage of the LV or missing anatomical structures are discarded. For motion tracking, subjects with failed image registration or outlier peak global strain values (positive circumferential strain, negative radial strain or positive longitudinal strain) are discarded.

Statistical analysis

Multiple linear regression is used to identify the associations between imaging phenotypes and cardiovascular risk factors, using the Python statsmodels library. The risk factors are provided by UK Biobank, including sex (31), age (derived using the date attending assessment centre (53), birth year (34) and birth month (52)), weight (21002), height (50), SBP (4080), DBP (4079), current smoking status (20116), alcohol intake, vigorous PA frequency (904), high cholesterol and diabetes. The number inside the parenthesis indicates the UK Biobank field ID. Alcohol intake in the unit of g/day is derived from self-reported alcohol intake, including average weekly intake of red wine (1568), champagne plus white wine intake (1578), beer plus cider (1588), spirits (1598) and fortified wine (1608). The quantity of each type of drink is multiplied by its standard drink size and reference alcohol content, then converted to consumption per day⁶⁷. High cholesterol is derived from self-reported non-cancer illness code (20002), using illness code 1473. Diabetes is derived similarly, using illness code 1220, 1221, 1222 and 1223. Mediation analysis is performed following Baron and Kenny's steps⁶⁸ and implemented also using the Python statsmodels library.

In the PheWAS, effects such as age, sex, weight and height are regressed out of the imaging phenotypes, similar to¹⁸, as they may confound with many non-imaging phenotypes. The non-imaging phenotypes are normalised to follow the Gaussian distribution $N(0, 1)$. Univariate cross correlation is then performed between each deconfounded imaging phenotype and each normalised non-imaging phenotype. The non-imaging phenotypes are grouped into 11 categories similar to¹⁸, including primary demographics (1001), early-life factors (1002), education and employment (1007), diet summary (1004), alcohol summary (100051), smoking summary (100058), physical activity (100054), physical measure summary (1006), self-reported medical conditions (1003), mental health (1018), cognitive function (100026). The number inside the parenthesis indicates the UK Biobank category ID listed at <http://biobank.ndph.ox.ac.uk/showcase/cats.cgi>. We use all non-imaging phenotypes that are available to us in our UK Biobank Application 18545 and that belong to the 11 categories. Then we perform data cleaning, discarding phenotypes with more than 90% missing data and keeping only one phenotype if there are two highly correlated phenotypes with correlation coefficient > 0.9999 .

Mendelian randomisation

Data sources for the genetic associations of each risk factor of interest are presented in Supplementary Table 17, including SBP, diabetes, birth weight, risk tolerance and fluid intelligence. The genetic instruments, the SNPs, were selected with $p < 5 \times 10^{-8}$. For fluid intelligence, due to the lack of genetic instruments, a p-value cut-off of 1×10^{-5} was used. To avoid weak-instrument bias, we calculated the F-statistics and only included genetic instruments with an F-statistic > 10 . We removed correlated SNPs ($r^2 > 0.1$) by keeping the SNP with the smallest p-value for the association with the risk factor of interest. Supplementary Tables 22-26 list the SNPs used for each risk factor. Genetic associations of imaging phenotypes were performed among genotyped Caucasian, adjusting for sex, age, height and genetic principal components. Three Mendelian randomisation methods were used⁵⁶: inverse-variance weighting (IVW), weighted median (WM) and MR-Egger^{69,70}. We assessed the heterogeneity statistics Q for IVW, Q' for MR-Egger and calculated the ratio statistic $Q_R = Q'/Q$ for model selection²⁸. A Q_R close to 1 indicates that IVW and MR-Egger models fit the data equally well, whereas a Q_R much less than 1 indicates that MR-Egger is better fitting. MR-PRESSO was used to identify outlier SNPs⁷¹. Outlier SNPs identified by MR-PRESSO were excluded from the analysis. Analysis was performed using the TwoSampleMR package in R⁷². We adjusted for multiple testing of 5 risk factors and 7 imaging phenotypes using Bonferroni correction.

Data availability

The raw imaging data and non-imaging participant characteristics are available from UK Biobank via a standard application procedure at <http://www.ukbiobank.ac.uk/register-apply>. The image analysis code is available at https://github.com/baiwenjia/ukbb_cardiac. For PheWAS, category IDs and field IDs are defined in `ukb_field_categories.py` and included in `perform_phenome_wide_association.py`. The associations between imaging phenotypes and non-imaging phenotypes can be browsed at <https://heartvis.doc.ic.ac.uk>.


Reporting summary

Further information on research design is available in the Life Sciences Reporting Summary linked to this paper.


References

58. Petersen, S. E. *et al.* UK Biobank's cardiovascular magnetic resonance protocol. *J. Cardiovasc. Magn. Reson.* **18**, 8 (2015).
59. Cerqueira, M. D. *et al.* Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. *Circulation* **105**, 539–542 (2002).
60. Rueckert, D. *et al.* Nonrigid registration using free-form deformations: application to breast MR images. *IEEE Transactions on Med. Imaging* **18**, 712–21 (1999).
61. Tobon-Gomez, C. *et al.* Benchmarking framework for myocardial tracking and deformation algorithms: An open access database. *Med. Image Analysis* **17**, 632–648 (2013).
62. Taylor, R. J. *et al.* Myocardial strain measurement with feature-tracking cardiovascular magnetic resonance: normal values. *Eur. Hear. J. - Cardiovasc. Imaging* **16**, 871–881 (2015).
63. Schuster, A. *et al.* Cardiovascular magnetic resonance feature-tracking assessment of myocardial mechanics: Intervendor agreement and considerations regarding reproducibility. *Clin. Radiol.* **70**, 989–998 (2015).
64. Puyol-Anton, E. *et al.* Fully automated myocardial strain estimation from cine MRI using convolutional neural networks. In *IEEE International Symposium on Biomedical Imaging*, 1139–1143 (2018).
65. Tsang, T. S. *et al.* Prediction of cardiovascular outcomes with left atrial size. *J. Am. Coll. Cardiol.* **47**, 1018–1023 (2006).
66. Maceira, A. M., Cosín-Sales, J., Roughton, M., Prasad, S. K. & Pennell, D. J. Reference left atrial dimensions and volumes by steady state free precession cardiovascular magnetic resonance. *J. Cardiovasc. Magn. Reson.* **12**, 65 (2010).
67. Evangelou, E. *et al.* New alcohol-related genes suggest shared genetic mechanisms with neuropsychiatric disorders. *Nat. Hum. Behav.* **3**, 950–961 (2019).
68. Baron, R. M. & Kenny, D. A. The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations. *J. Pers. Soc. Psychol.* **51**, 1173–1182 (1986).
69. Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. *Genet. Epidemiol.* **40**, 304–314 (2016).
70. Burgess, S. & Thompson, S. G. Interpreting findings from Mendelian randomization using the MR-Egger method. *Eur. J. Epidemiol.* **32**, 377–389 (2017).
71. Verbanck, M., Chen, C.-Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat. Genet.* **50**, 693–698 (2018).
72. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the human phenome. *eLife* **7** (2018).
73. Evangelou, E. *et al.* Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nat. Genet.* **50**, 1412–1425 (2018).
74. Morris, A. *et al.* Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. *Nat. Genet.* **44**, 981–990 (2012).
75. Warrington, N. M. *et al.* Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors. *Nat. Genet.* **51**, 804–814 (2019).
76. Linnér, R. K. *et al.* Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. *Nat. Genet.* **51**, 245–257 (2019).
77. Davies, G. *et al.* Genome-wide association studies establish that human intelligence is highly heritable and polygenic. *Mol. Psychiatry* **16**, 996–1005 (2011).

Extended Data Figures



Extended Data Figure 1. The conditional plots of imaging phenotypes against birth weight. The dark line denotes the conditional plot of an imaging phenotype against birth weight, with other variables (sex, age, sex * age, weight, height, SBP, DBP, current smoking status, alcohol intake, vigorous PA frequency, high cholesterol and diabetes) set to their mean. The grey area denotes the 95% confidence interval. $n = 12,169$ subjects were analysed with available birth weight information. The p-values were calculated from two-sided t-tests.



Extended Data Figure 2. Mediation model for LVM, brain volume and fluid intelligence score. The relationship between LVM and fluid intelligence score (path c) is 26% (difference between c and c') mediated by total brain volume. $n = 18,369$ subjects were analysed with available fluid intelligence information. The values are depicted as regression coefficient (two-sided t-test p-value) for standardised imaging phenotypes.

Supplementary Tables

	For analysis	After quality control
Short-axis image	26,904	26,521 (98.6%)
Long-axis image	26,602	26,240 (98.6%)
Aortic image	26,300	25,673 (97.6%)

Supplementary Table 1. Number of subjects with available raw images for analysis and after quality control. In total, imaging phenotypes were available for 26,893 subjects after quality control.

	Women (n = 13,969)	Men (n = 12,924)
Age (year)	62.8 (7.4)	64.2 (7.6)
Race (%)		
Caucasian	97.4	96.8
Other ethnicities	2.4	2.9
Unknown	0.2	0.4
Weight (kg)	69.2 (13.1)	83.9 (13.5)
Height (cm)	162.7 (6.2)	176.1 (6.6)
BMI (kg/m ²)	26.2 (4.8)	27.0 (3.9)
SBP (mmHg)	133.9 (18.5)	140.6 (16.8)
DBP (mmHg)	77.3 (10.0)	80.9 (9.8)
Life-style		
Current smoking (%)	3.1	4.3
Alcohol intake (gram per day)	13.3 (12.3)	26.1 (22.0)
Vigorous PA (days per week)	1.8 (1.8)	2.2 (1.9)
Self-reported diseases		
Hypertension (%)	17.9	26.4
High cholesterol (%)	9.0	14.3
Cardiac disease (%)	3.9	8.8
PVD (%)	0.0	0.2
Diabetes (%)	3.1	6.3
Stroke (%)	0.8	1.3
Asthma (%)	10.1	9.3
COPD (%)	0.4	0.8
Bronchitis (%)	1.8	1.8
Parkinson's (%)	0.1	0.2
Dementia (%)	0.0	0.1
Depression (%)	9.9	5.8

Supplementary Table 2. Basic participant characteristics. n = 26,893 subjects were analysed. Values are depicted as mean (standard deviation). BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; PA: physical activity; PVD: peripheral vascular disease; COPD: chronic obstructive pulmonary disease.

	Women (n = 13,969)	Men (n = 12,924)
Left ventricle		
LV end-diastolic volume (mL)	129.5 (22.5)	168.8 (32.1)
LV end-systolic volume (mL)	50.5 (12.6)	71.5 (19.4)
LV stroke volume (mL)	79.0 (14.4)	97.3 (19.3)
LV ejection fraction (%)	61.1 (5.6)	57.8 (6.1)
LV cardiac output (L/min)	5.0 (1.1)	5.9 (1.3)
LV myocardial mass (g)	70.9 (12.2)	102.9 (18.3)
LV wall thickness (mm)	5.2 (0.5)	6.2 (0.7)
Global peak strain E_{cc} (%)	-23.4 (3.0)	-21.1 (3.2)
Global peak strain E_{rr} (%)	47.5 (7.8)	42.2 (7.8)
Global peak strain E_{ll} (%)	-19.1 (2.7)	-17.8 (2.6)
Right ventricle		
RV end-diastolic volume (mL)	134.2 (24.3)	181.3 (33.3)
RV end-systolic volume (mL)	54.9 (13.4)	81.4 (19.4)
RV stroke volume (mL)	79.3 (15.1)	99.9 (20.0)
RV ejection fraction (%)	59.3 (5.7)	55.2 (5.9)
Left atrium		
LA maximal volume (mL)	67.6 (19.2)	78.7 (25.8)
LA minimal volume (mL)	26.5 (12.0)	32.4 (17.9)
LA stroke volume (mL)	41.1 (10.1)	46.3 (12.7)
LA ejection fraction (%)	61.9 (8.6)	60.5 (9.7)
Right atrium		
RA maximal volume (mL)	75.2 (19.5)	97.8 (29.8)
RA minimal volume (mL)	38.1 (12.5)	54.7 (20.8)
RA stroke volume (mL)	37.1 (11.1)	43.1 (14.4)
RA ejection fraction (%)	49.5 (8.8)	44.6 (9.0)
Ascending aorta		
AAo maximal area (mm ²)	775.9 (156.0)	925.3 (189.5)
AAo minimal area (mm ²)	703.3 (155.1)	841.8 (185.9)
AAo distensibility (10 ⁻³ mmHg ⁻¹)	1.9 (1.5)	1.9 (1.2)
Descending aorta		
DAo maximal area (mm ²)	421.4 (71.0)	529.5 (91.6)
DAo minimal area (mm ²)	368.3 (68.3)	468.2 (87.3)
DAo distensibility (10 ⁻³ mmHg ⁻¹)	2.5 (1.7)	2.5 (1.4)

Supplementary Table 3. Statistics of global imaging phenotypes for the heart and aorta. n = 26,893 subjects were analysed. The values are depicted as mean (standard deviation).

Segment	Women (n = 13,969)		Men (n = 12,924)	
	Wall thickness (mm)		Wall thickness (mm)	
Basal	1	6.1 (0.9)	7.2 (1.1)	
	2	4.6 (1.0)	5.3 (1.2)	
	3	4.9 (1.0)	5.7 (1.1)	
	4	5.6 (0.8)	6.8 (1.0)	
	5	5.8 (0.7)	6.8 (0.8)	
	6	5.8 (0.7)	6.8 (0.9)	
Mid	7	5.1 (0.6)	6.2 (0.8)	
	8	5.7 (0.7)	6.9 (0.9)	
	9	5.9 (0.8)	7.2 (1.0)	
	10	5.4 (0.7)	6.6 (0.8)	
	11	5.2 (0.6)	6.2 (0.8)	
	12	5.1 (0.6)	6.1 (0.8)	
Apical	13	4.2 (0.6)	5.1 (0.7)	
	14	4.4 (0.6)	5.3 (0.7)	
	15	4.1 (0.6)	5.0 (0.7)	
	16	4.3 (0.6)	5.2 (0.7)	
Global	5.2 (0.5)	6.2 (0.7)		

Supplementary Table 4. Statistics of regional and global myocardial wall thickness. n = 26,893 subjects were analysed. The values are depicted as mean (standard deviation).

Segment	Women (n = 13,969)		Men (n = 12,924)		
	E_{cc} (%)	E_{rr} (%)	E_{cc} (%)	E_{rr} (%)	
Basal	1	-23.9 (5.2)	39.3 (12.9)	-22.3 (5.3)	35.5 (12.8)
	2	-23.9 (6.6)	30.6 (11.6)	-18.2 (6.9)	24.6 (11.2)
	3	-20.3 (6.1)	35.6 (13.2)	-19.0 (5.2)	27.4 (13.0)
	4	-19.0 (5.9)	62.7 (17.8)	-19.1 (5.4)	51.4 (16.0)
	5	-27.6 (5.2)	67.6 (16.2)	-25.0 (5.3)	60.1 (14.3)
	6	-27.1 (5.5)	56.3 (18.7)	-26.0 (5.1)	53.9 (16.7)
Mid	7	-27.9 (5.3)	52.8 (13.2)	-24.7 (5.2)	47.2 (12.6)
	8	-27.3 (5.5)	43.7 (10.6)	-24.8 (5.4)	40.5 (10.3)
	9	-23.5 (7.2)	49.3 (12.1)	-21.8 (5.8)	44.3 (11.1)
	10	-15.6 (5.0)	51.0 (14.0)	-15.5 (4.6)	45.4 (12.4)
	11	-22.9 (5.4)	57.1 (12.7)	-20.7 (5.3)	50.5 (11.4)
	12	-20.3 (5.2)	53.6 (12.9)	-18.0 (4.8)	46.7 (12.1)
Apical	13	-30.1 (5.7)	49.9 (13.5)	-27.0 (5.9)	47.2 (13.6)
	14	-30.9 (5.8)	44.3 (12.6)	-28.5 (5.8)	41.8 (13.0)
	15	-23.4 (6.5)	58.0 (14.5)	-23.8 (6.5)	53.5 (14.0)
	16	-26.1 (5.7)	58.0 (13.5)	-24.9 (6.0)	54.7 (13.4)
Global	-23.4 (3.0)	47.5 (7.8)	-21.1 (3.2)	42.2 (7.8)	

Supplementary Table 5. Statistics of regional and global peak circumferential strain E_{cc} and peak radial strain E_{rr} . n = 26,893 subjects were analysed. The values are depicted as mean (standard deviation).

Segment		Women (n = 13,969)	Men (n = 12,924)
		E ₁₁ (%)	E ₁₁ (%)
Basal	1	-27.3 (7.2)	-27.1 (6.7)
	2	-32.6 (7.8)	-32.2 (7.0)
Mid	3	-14.3 (5.0)	-12.5 (4.9)
	4	-18.4 (5.6)	-15.1 (5.2)
Apical	5	-11.1 (4.6)	-10.6 (4.5)
	6	-17.2 (4.7)	-15.5 (4.9)
Global		-19.1 (2.7)	-17.8 (2.6)

Supplementary Table 6. Statistics of regional and global peak longitudinal strain E₁₁. n = 26,893 subjects were analysed. The values are depicted as mean (standard deviation).

	LVM (g)	LVEDV (mL)	LVEF (%)	RVEDV (mL)	RVEF (%)
Sex	53.0 _[49.8,56.3] (p=3×10 ⁻²¹⁸)	53.1 _[47.4,58.8] (p=2.9×10 ⁻⁷⁴)	-3.2 _[-3.4,-3.1] (p=10 ⁻³²⁴)	71.1 _[65.0,77.2] (p=7.7×10 ⁻¹¹⁶)	-4.1 _[-4.2,-3.9] (p=10 ⁻³²⁴)
Age, per 7.5 yr	-1.0 _[-1.2,-0.7] (p=2.2×10 ⁻¹²)	-5.9 _[-6.4,-5.5] (p=2.5×10 ⁻¹³⁶)	0.3 _[0.3,0.4] (p=1.1×10 ⁻¹⁹)	-6.1 _[-6.6,-5.7] (p=4.7×10 ⁻¹³⁰)	0.5 _[0.4,0.6] (p=1.6×10 ⁻³⁷)
Sex * Age, per 7.5 yr	-2.4 _[-2.8,-2.1] (p=5.6×10 ⁻³⁶)	-1.5 _[-2.2,-0.8] (p=8.6×10 ⁻⁶)		-2.6 _[-3.3,-1.9] (p=4.6×10 ⁻¹³)	
	LAV max (mL)	LAEF (%)	RAV max (mL)	RAEF (%)	
Sex	10.6 _[10.1,11.2] (p=2.6×10 ⁻²⁹⁷)	-0.9 _[-1.1,-0.7] (p=1.7×10 ⁻¹⁵)	22.7 _[22.1,23.3] (p=10 ⁻³²⁴)	-8.9 _[-10.8,-7.0] (p=1.4×10 ⁻¹⁹)	
Age, per 7.5 yr	-2.0 _[-2.3,-1.7] (p=9.1×10 ⁻⁴⁴)	-0.8 _[-0.9,-0.7] (p=2.3×10 ⁻⁴³)	-1.0 _[-1.3,-0.7] (p=1.7×10 ⁻⁹)	-0.2 _[-0.4,-0.1] (p=0.003)	
Sex * Age, per 7.5 yr				0.5 _[0.3,0.7] (p=2.3×10 ⁻⁵)	
	AAo max area (mm ²)	AAo distensibility	DAo max area (mm ²)	DAo distensibility	
Sex	143.9 _[139.5,148.3] (p=10 ⁻³²⁴)	-0.9 _[-1.2,-0.6] (p=2.1×10 ⁻¹⁰)	104.9 _[102.8,106.9] (p=10 ⁻³²⁴)	-1.1 _[-1.5,-0.8] (p=1.7×10 ⁻¹⁰)	
Age, per 7.5 yr	29.3 _[27.1,31.5] (p=6.1×10 ⁻¹⁴⁶)	-0.7 _[-0.7,-0.7] (p=10 ⁻³²⁴)	20.8 _[19.8,21.9] (p=10 ⁻³²⁴)	-0.8 _[-0.8,-0.7] (p=10 ⁻³²⁴)	
Sex * Age, per 7.5 yr		0.1 _[0.1,0.2] (p=8.4×10 ⁻¹⁴)		0.1 _[0.1,0.2] (p=10 ⁻¹¹)	

Supplementary Table 7. Associations of selected imaging phenotypes with sex and age. After excluding non-Caucasian subjects and subjects with CVDs, n = 23,415 subjects were included in the analysis. The values are depicted as regression coefficient β [95% confidence interval] (two-sided t-test p-value). For continuous variables, the coefficient describes the effect per standard deviation of the variable. For binary variables, the coefficient describes the effect with a change in the variable from 0 to 1. Female is coded as 0.

	LVM (g)	LVEDV (mL)	LVEF (%)	RVEDV (mL)	RVEF (%)
Sex	30.2 _[27.4,33.0] (<i>p</i> =10 ⁻⁹⁶)	22.5 _[17.0,28.0] (<i>p</i> =10 ⁻¹⁵)	-2.5 _[-2.8,-2.3] (<i>p</i> =3.6×10 ⁻⁸⁹)	41.5 _[35.6,47.4] (<i>p</i> =3.2×10 ⁻⁴³)	-3.7 _[-3.9,-3.5] (<i>p</i> =3.7×10 ⁻¹⁹³)
Age, per 7.5 yr	-1.2 _[-1.4,-0.9] (<i>p</i> =8×10 ⁻²⁰)	-5.2 _[-5.6,-4.7] (<i>p</i> =2.3×10 ⁻⁹⁴)	-0.0 _[-0.1,0.1] (<i>p</i> =0.903)	-4.2 _[-4.7,-3.7] (<i>p</i> =3.6×10 ⁻⁵⁶)	-0.1 _[-0.1,0.0] (<i>p</i> =0.250)
Sex * Age, per 7.5 yr	-1.6 _[-1.9,-1.3] (<i>p</i> =4×10 ⁻²²)	-0.9 _[-1.5,-0.3] (<i>p</i> =0.006)		-2.2 _[-2.9,-1.5] (<i>p</i> =2.7×10 ⁻¹⁰)	
Weight, per 15.1 kg	8.2 _[8.0,8.4] (<i>p</i> =10 ⁻³²⁴)	8.4 _[8.0,8.8] (<i>p</i> =10 ⁻³²⁴)	0.1 _[0.0,0.2] (<i>p</i> =0.035)	9.2 _[8.8,9.7] (<i>p</i> =10 ⁻³²⁴)	-0.4 _[-0.5,-0.3] (<i>p</i> =1.6×10 ⁻¹²)
Height, per 9.2 cm	3.8 _[3.5,4.0] (<i>p</i> =3.5×10 ⁻¹⁷²)	10.7 _[10.2,11.2] (<i>p</i> =10 ⁻³²⁴)	-0.5 _[-0.7,-0.4] (<i>p</i> =2×10 ⁻¹⁶)	11.2 _[10.6,11.7] (<i>p</i> =10 ⁻³²⁴)	-0.1 _[-0.3,-0.0] (<i>p</i> =0.029)
SBP, per 18.0 mmHg	4.8 _[4.6,5.1] (<i>p</i> =10 ⁻³²⁴)	5.8 _[5.3,6.3] (<i>p</i> =2.4×10 ⁻¹³⁰)	0.9 _[0.8,1.0] (<i>p</i> =4.9×10 ⁻⁴⁹)	3.0 _[2.5,3.5] (<i>p</i> =4.8×10 ⁻³²)	1.6 _[1.5,1.7] (<i>p</i> =1.4×10 ⁻¹⁶¹)
DBP, per 10.0 mmHg	-1.4 _[-1.7,-1.2] (<i>p</i> =5.5×10 ⁻³⁵)	-5.4 _[-5.8,-4.9] (<i>p</i> =1.1×10 ⁻¹²⁰)	-0.7 _[-0.8,-0.6] (<i>p</i> =5.8×10 ⁻³⁸)	-4.3 _[-4.8,-3.8] (<i>p</i> =4.3×10 ⁻⁶⁸)	-0.8 _[-0.9,-0.7] (<i>p</i> =1.3×10 ⁻⁴⁵)
Smoking status	2.4 _[1.5,3.2] (<i>p</i> =6.7×10 ⁻⁸)	-1.3 _[-3.0,0.3] (<i>p</i> =0.118)	-0.4 _[-0.9,-0.0] (<i>p</i> =0.037)	-4.4 _[-6.2,-2.6] (<i>p</i> =1.2×10 ⁻⁶)	-0.4 _[-0.8,0.1] (<i>p</i> =0.086)
Alcohol, per 18.7 g/d	1.0 _[0.8,1.1] (<i>p</i> =3.4×10 ⁻²⁷)	1.4 _[1.1,1.8] (<i>p</i> =7.7×10 ⁻¹⁷)	-0.0 _[-0.1,0.0] (<i>p</i> =0.364)	1.1 _[0.7,1.5] (<i>p</i> =3.9×10 ⁻⁹)	0.0 _[-0.1,0.1] (<i>p</i> =0.472)
PA, per 1.9 d/w	2.1 _[1.9,2.3] (<i>p</i> =6.4×10 ⁻¹³²)	4.3 _[3.9,4.6] (<i>p</i> =7.1×10 ⁻¹⁴⁴)	-0.2 _[-0.2,-0.1] (<i>p</i> =1.1×10 ⁻⁴)	4.7 _[4.3,5.0] (<i>p</i> =2.1×10 ⁻¹⁵⁰)	-0.2 _[-0.3,-0.1] (<i>p</i> =3.2×10 ⁻⁸)
High cholesterol	-0.4 _[-0.9,0.1] (<i>p</i> =0.138)	-2.8 _[-3.9,-1.8] (<i>p</i> =7.4×10 ⁻⁸)	0.2 _[-0.1,0.4] (<i>p</i> =0.230)	-2.9 _[-4.0,-1.8] (<i>p</i> =3.5×10 ⁻⁷)	0.3 _[0.0,0.5] (<i>p</i> =0.046)
Diabetes	-1.0 _[-1.8,-0.1] (<i>p</i> =0.025)	-8.7 _[-10.3,-7.0] (<i>p</i> =1.4×10 ⁻²⁴)	-1.0 _[-1.4,-0.5] (<i>p</i> =5.1×10 ⁻⁶)	-11.1 _[-12.9,-9.3] (<i>p</i> =3.4×10 ⁻³⁴)	-0.7 _[-1.1,-0.3] (<i>p</i> =5×10 ⁻⁴)
	LAV max (mL)	LAEF (%)	RAV max (mL)	RAEF (%)	
Sex	-1.0 _[-1.8,-0.1] (<i>p</i> =0.033)	0.7 _[0.4,1.1] (<i>p</i> =1.1×10 ⁻⁴)	9.0 _[8.0,10.0] (<i>p</i> =8.2×10 ⁻⁶⁷)	-8.7 _[-10.7,-6.6] (<i>p</i> =5.4×10 ⁻¹⁶)	
Age, per 7.5 yr	-2.3 _[-2.6,-1.9] (<i>p</i> =7.2×10 ⁻⁴³)	-1.0 _[-1.1,-0.8] (<i>p</i> =1.4×10 ⁻⁴³)	0.8 _[0.4,1.1] (<i>p</i> =5.6×10 ⁻⁵)	-0.7 _[-0.9,-0.5] (<i>p</i> =2.1×10 ⁻¹³)	
Sex * Age, per 7.5 yr				0.6 _[0.3,0.8] (<i>p</i> =2×10 ⁻⁶)	
Weight, per 15.1 kg	7.8 _[7.4,8.2] (<i>p</i> =10 ⁻³²⁴)	-0.9 _[-1.1,-0.8] (<i>p</i> =3.2×10 ⁻³¹)	-0.4 _[-0.8,0.0] (<i>p</i> =0.078)	0.1 _[-0.1,0.2] (<i>p</i> =0.344)	
Height, per 9.2 cm	1.8 _[1.4,2.3] (<i>p</i> =4.1×10 ⁻¹⁵)	-0.4 _[-0.6,-0.2] (<i>p</i> =1.8×10 ⁻⁵)	9.7 _[9.1,10.2] (<i>p</i> =2.8×10 ⁻²⁸⁰)	-0.9 _[-1.1,-0.7] (<i>p</i> =1.5×10 ⁻¹⁸)	
SBP, per 18.0 mmHg	4.8 _[4.4,5.3] (<i>p</i> =8.3×10 ⁻¹¹⁵)	-0.0 _[-0.2,0.1] (<i>p</i> =0.647)	-0.1 _[-0.6,0.4] (<i>p</i> =0.713)	0.9 _[0.7,1.0] (<i>p</i> =3.9×10 ⁻²¹)	
DBP, per 10.0 mmHg	-4.1 _[-4.5,-3.7] (<i>p</i> =1.7×10 ⁻⁸⁸)	0.5 _[0.3,0.6] (<i>p</i> =8.9×10 ⁻⁸)	-1.5 _[-2.0,-1.1] (<i>p</i> =6.6×10 ⁻¹¹)	0.0 _[-0.1,0.2] (<i>p</i> =0.738)	
Smoking status	-3.5 _[-5.0,-2.1] (<i>p</i> =2.9×10 ⁻⁶)	-0.2 _[-0.9,0.4] (<i>p</i> =0.436)	-5.4 _[-7.1,-3.7] (<i>p</i> =5.3×10 ⁻¹⁰)	0.1 _[-0.6,0.7] (<i>p</i> =0.835)	
Alcohol, per 18.7 g/d	1.1 _[0.8,1.4] (<i>p</i> =4.5×10 ⁻¹³)	-0.2 _[-0.3,-0.1] (<i>p</i> =0.003)	0.6 _[0.2,0.9] (<i>p</i> =7.6×10 ⁻⁴)	-0.1 _[-0.3,-0.0] (<i>p</i> =0.035)	
PA, per 1.9 d/w	2.6 _[2.3,2.9] (<i>p</i> =9.7×10 ⁻⁶⁹)	-0.4 _[-0.5,-0.2] (<i>p</i> =3.4×10 ⁻⁹)	3.1 _[2.8,3.4] (<i>p</i> =3.9×10 ⁻⁷⁴)	-0.5 _[-0.7,-0.4] (<i>p</i> =1.8×10 ⁻¹⁷)	
High cholesterol	-1.7 _[-2.6,-0.8] (<i>p</i> =3.7×10 ⁻⁴)	0.3 _[-0.1,0.7] (<i>p</i> =0.111)	-3.3 _[-4.3,-2.2] (<i>p</i> =1.6×10 ⁻⁹)	0.3 _[-0.1,0.7] (<i>p</i> =0.196)	
Diabetes	-3.5 _[-5.0,-2.1] (<i>p</i> =2.6×10 ⁻⁶)	-1.1 _[-1.7,-0.4] (<i>p</i> =9.3×10 ⁻⁴)	-7.2 _[-8.9,-5.5] (<i>p</i> =1.1×10 ⁻¹⁶)	-0.0 _[-0.6,0.6] (<i>p</i> =0.960)	
	AAo max area (mm ²)	AAo distensibility	DAo max area (mm ²)	DAo distensibility	
Sex	42.2 _[35.2,49.2] (<i>p</i> =8.7×10 ⁻³²)	-0.6 _[-0.9,-0.2] (<i>p</i> =5.5×10 ⁻⁴)	49.1 _[45.9,52.2] (<i>p</i> =2.5×10 ⁻¹⁹⁷)	-0.7 _[-1.0,-0.3] (<i>p</i> =7×10 ⁻⁴)	
Age, per 7.5 yr	44.0 _[41.4,46.6] (<i>p</i> =3.7×10 ⁻²⁴¹)	-0.7 _[-0.7,-0.6] (<i>p</i> =10 ⁻³²⁴)	27.2 _[26.0,28.3] (<i>p</i> =10 ⁻³²⁴)	-0.7 _[-0.7,-0.6] (<i>p</i> =10 ⁻³²⁴)	
Sex * Age, per 7.5 yr		0.1 _[0.1,0.1] (<i>p</i> =3.9×10 ⁻⁸)		0.1 _[0.1,0.1] (<i>p</i> =6.7×10 ⁻⁶)	
Weight, per 15.1 kg	36.6 _[33.6,39.6] (<i>p</i> =1.8×10 ⁻¹²²)	0.0 _[0.0,0.1] (<i>p</i> =2.4×10 ⁻⁴)	26.2 _[24.9,27.6] (<i>p</i> =1.6×10 ⁻³⁰⁰)	-0.0 _[-0.1,-0.0] (<i>p</i> =0.023)	
Height, per 9.2 cm	29.5 _[25.9,33.1] (<i>p</i> =2.2×10 ⁻⁵⁷)	-0.1 _[-0.1,-0.0] (<i>p</i> =1.5×10 ⁻⁵)	14.3 _[12.7,16.0] (<i>p</i> =3.2×10 ⁻⁶⁶)	0.0 _[-0.0,0.1] (<i>p</i> =0.335)	
SBP, per 18.0 mmHg	-13.5 _[-16.8,-10.2] (<i>p</i> =1.2×10 ⁻¹⁵)	-0.2 _[-0.2,-0.2] (<i>p</i> =1.1×10 ⁻⁴¹)	-0.2 _[-1.7,1.3] (<i>p</i> =0.783)	-0.3 _[-0.3,-0.2] (<i>p</i> =2.9×10 ⁻⁵³)	
DBP, per 10.0 mmHg	40.5 _[37.3,43.6] (<i>p</i> =2.4×10 ⁻¹³⁵)	-0.1 _[-0.1,-0.1] (<i>p</i> =2.2×10 ⁻¹⁵)	10.8 _[9.4,12.3] (<i>p</i> =2.5×10 ⁻⁴⁹)	-0.1 _[-0.1,-0.0] (<i>p</i> =1.9×10 ⁻⁶)	
Smoking status	10.3 _[-1.6,22.2] (<i>p</i> =0.090)	0.0 _[-0.1,0.1] (<i>p</i> =0.636)	14.5 _[9.1,19.9] (<i>p</i> =1.3×10 ⁻⁷)	0.1 _[-0.0,0.2] (<i>p</i> =0.054)	
Alcohol, per 18.7 g/d	11.7 _[9.3,14.1] (<i>p</i> =1.6×10 ⁻²¹)	-0.0 _[-0.0,0.0] (<i>p</i> =0.076)	4.4 _[3.3,5.4] (<i>p</i> =3.3×10 ⁻¹⁵)	-0.0 _[-0.1,-0.0] (<i>p</i> =0.010)	
PA, per 1.9 d/w	10.5 _[8.2,12.8] (<i>p</i> =5.2×10 ⁻¹⁹)	0.0 _[0.0,0.1] (<i>p</i> =1.5×10 ⁻⁵)	6.3 _[5.3,7.4] (<i>p</i> =4.9×10 ⁻³³)	0.0 _[0.0,0.1] (<i>p</i> =5.9×10 ⁻⁵)	
High cholesterol	-0.0 _[-7.3,7.3] (<i>p</i> =0.998)	-0.0 _[-0.1,0.1] (<i>p</i> =0.955)	-5.1 _[-8.3,-1.8] (<i>p</i> =0.003)	-0.0 _[-0.1,0.1] (<i>p</i> =0.799)	
Diabetes	-19.7 _[-31.5,-7.9] (<i>p</i> =0.001)	0.0 _[-0.1,0.1] (<i>p</i> =0.991)	-17.6 _[-22.9,-12.3] (<i>p</i> =8.9×10 ⁻¹¹)	-0.1 _[-0.2,0.1] (<i>p</i> =0.317)	

Supplementary Table 8. Associations of imaging phenotypes with cardiovascular risk factors. n = 19,988 subjects were analysed with available information for all independent variables. The values are depicted as regression coefficient β [95% confidence interval] (two-sided t-test p-value). Independent variables include sex, age, weight, height, systolic blood pressure (SBP), diastolic blood pressure (DBP), current smoking status, alcohol intake, vigorous physical activity (PA) frequency, high cholesterol, diabetes. For continuous variables, the coefficient describes the effect per standard deviation of the variable. For binary variables, the coefficient describes the effect with a change in the variable from 0 to 1. Female is coded as 0.

Category	Code	Meaning
Hypertension	1065	Hypertension
	1072	Essential hypertension
	1073	Gestational hypertension/pre-eclampsia
High cholesterol	1473	High cholesterol
Cardiac disease	1066	Heart/cardiac problem
	1074	Angina
	1075	Heart attack/myocardial infarction
	1076	Heart failure/pulmonary odema
	1077	Heart arrhythmia
	1471	Atrial fibrillation
	1483	Atrial flutter
	1484	Wolff Parkinson white/WPW syndrome
	1485	Irregular heart beat
	1486	Sick sinus syndrome
	1487	SVT/supraventricular tachycardia
	1078	Heart valve problem/heart murmur
	1584	Mitral valve disease
	1585	Mitral regurgitation/incompetence
	1586	Aortic valve disease
	1587	Aortic regurgitation/incompetence
	1079	Cardiomyopathy
1588	Hypertrophic cardiomyopathy (HCM/HOCM)	
1080	Pericardial problem	
1589	Pericarditis	
1590	Pericardial effusion	
PVD	1067	Peripheral vascular disease
	1087	Leg claudication/intermittent claudication
	1088	Arterial embolism
	1492	Aortic aneurysm
	1591	Aortic aneurysm rupture
	1592	Aortic dissection
Diabetes	1220	Diabetes
	1221	Gestational diabetes
	1222	Type 1 diabetes
	1223	Type 2 diabetes
Stroke	1081	Stroke
	1086	Subarachnoid haemorrhage
	1491	Brain haemorrhage
	1583	Ischaemic stroke
Asthma	1111	Asthma
COPD	1112	Chronic obstructive airways disease/COPD
Bronchitis	1113	Emphysema/chronic bronchitis
	1412	Bronchitis
	1472	Emphysema
	1496	Alpha-1 antitrypsin deficiency
Parkinson's	1262	Parkinson's disease
Dementia	1263	Dementia/Alzheimer's/cognitive impairment
Depression	1286	Depression
	1531	Post-natal depression

Supplementary Table 9. Categories of common diseases in participants. Defined by self-reported disease code (UK Biobank field ID 20002).

	LVM per 22.2 g	LVEDV per 33.8 mL	LVEF per 6.1 %	RVEDV per 37.3 mL	RVEF per 6.1 %
Hypertension	1.66 _[1.58,1.75] (<i>p</i> =3×10 ⁻⁸⁴)	1.05 _[1.01,1.09] (<i>p</i> =0.024)	1.10 _[1.07,1.13] (<i>p</i> =2×10 ⁻¹⁰)	0.96 _[0.92,1.00] (<i>p</i> =0.072)	1.14 _[1.11,1.18] (<i>p</i> =6.2×10 ⁻¹⁷)
High cholesterol	0.97 _[0.91,1.03] (<i>p</i> =0.361)	0.87 _[0.82,0.92] (<i>p</i> =2.1×10 ⁻⁷)	1.00 _[0.96,1.03] (<i>p</i> =0.869)	0.86 _[0.82,0.91] (<i>p</i> =4×10 ⁻⁷)	1.01 _[0.97,1.05] (<i>p</i> =0.534)
Cardiac disease	1.41 _[1.31,1.53] (<i>p</i> =1.8×10 ⁻¹⁹)	1.44 _[1.36,1.53] (<i>p</i> =8.3×10 ⁻³³)	0.76 _[0.72,0.79] (<i>p</i> =4.2×10 ⁻³⁵)	1.10 _[1.03,1.18] (<i>p</i> =0.008)	0.84 _[0.80,0.88] (<i>p</i> =8.1×10 ⁻¹⁴)
PVD	1.34 _[0.81,2.21] (<i>p</i> =0.253)	1.44 _[1.01,2.04] (<i>p</i> =0.044)	0.80 _[0.59,1.09] (<i>p</i> =0.152)	1.07 _[0.65,1.76] (<i>p</i> =0.782)	0.81 _[0.58,1.11] (<i>p</i> =0.186)
Diabetes	0.94 _[0.86,1.03] (<i>p</i> =0.210)	0.66 _[0.61,0.72] (<i>p</i> =1.8×10 ⁻²²)	0.90 _[0.86,0.95] (<i>p</i> =1.8×10 ⁻⁴)	0.56 _[0.52,0.62] (<i>p</i> =1.3×10 ⁻³⁷)	0.94 _[0.89,0.99] (<i>p</i> =0.028)
Stroke	0.97 _[0.79,1.17] (<i>p</i> =0.724)	0.91 _[0.78,1.07] (<i>p</i> =0.259)	0.94 _[0.84,1.04] (<i>p</i> =0.228)	0.82 _[0.69,0.97] (<i>p</i> =0.024)	0.90 _[0.80,1.00] (<i>p</i> =0.056)
Asthma	1.03 _[0.96,1.10] (<i>p</i> =0.482)	0.95 _[0.90,1.01] (<i>p</i> =0.074)	0.99 _[0.95,1.03] (<i>p</i> =0.527)	0.90 _[0.85,0.96] (<i>p</i> =8.7×10 ⁻⁴)	1.04 _[1.00,1.09] (<i>p</i> =0.044)
COPD	0.99 _[0.78,1.27] (<i>p</i> =0.963)	0.69 _[0.55,0.86] (<i>p</i> =8.8×10 ⁻⁴)	0.88 _[0.77,1.01] (<i>p</i> =0.069)	0.54 _[0.42,0.68] (<i>p</i> =2.2×10 ⁻⁷)	0.85 _[0.74,0.98] (<i>p</i> =0.021)
Bronchitis	0.95 _[0.81,1.12] (<i>p</i> =0.565)	0.83 _[0.72,0.94] (<i>p</i> =0.005)	0.90 _[0.83,0.98] (<i>p</i> =0.019)	0.78 _[0.68,0.89] (<i>p</i> =3.9×10 ⁻⁴)	0.92 _[0.85,1.01] (<i>p</i> =0.075)
Parkinson's	0.64 _[0.37,1.12] (<i>p</i> =0.117)	1.02 _[0.69,1.51] (<i>p</i> =0.916)	1.20 _[0.89,1.62] (<i>p</i> =0.235)	1.13 _[0.73,1.73] (<i>p</i> =0.583)	1.14 _[0.83,1.55] (<i>p</i> =0.413)
Dementia	0.25 _[0.08,0.82] (<i>p</i> =0.023)	0.41 _[0.17,0.99] (<i>p</i> =0.048)	0.97 _[0.58,1.62] (<i>p</i> =0.899)	0.47 _[0.19,1.13] (<i>p</i> =0.090)	1.09 _[0.63,1.91] (<i>p</i> =0.751)
Depression	0.97 _[0.90,1.06] (<i>p</i> =0.517)	0.93 _[0.87,1.00] (<i>p</i> =0.046)	0.98 _[0.93,1.02] (<i>p</i> =0.279)	0.89 _[0.83,0.96] (<i>p</i> =0.001)	1.01 _[0.96,1.06] (<i>p</i> =0.693)
	LAV max per 23.2 mL	LAEF per 9.1 %	RAV max per 27.4 mL	RAEF per 9.2 %	
Hypertension	1.10 _[1.07,1.14] (<i>p</i> =6.5×10 ⁻¹⁰)	0.99 _[0.96,1.02] (<i>p</i> =0.362)	0.92 _[0.89,0.95] (<i>p</i> =9.3×10 ⁻⁷)	1.12 _[1.08,1.15] (<i>p</i> =8.8×10 ⁻¹³)	
High cholesterol	0.92 _[0.88,0.96] (<i>p</i> =3.8×10 ⁻⁵)	1.01 _[0.97,1.04] (<i>p</i> =0.758)	0.88 _[0.84,0.92] (<i>p</i> =2.1×10 ⁻⁸)	1.00 _[0.96,1.04] (<i>p</i> =0.914)	
Cardiac disease	1.49 _[1.42,1.56] (<i>p</i> =1.5×10 ⁻⁶³)	0.61 _[0.58,0.63] (<i>p</i> =2.3×10 ⁻¹⁰⁷)	1.28 _[1.22,1.34] (<i>p</i> =2.2×10 ⁻²²)	0.71 _[0.67,0.74] (<i>p</i> =1.8×10 ⁻³⁸)	
PVD	1.20 _[0.89,1.61] (<i>p</i> =0.230)	0.70 _[0.52,0.94] (<i>p</i> =0.017)	1.32 _[1.01,1.72] (<i>p</i> =0.041)	0.82 _[0.56,1.19] (<i>p</i> =0.300)	
Diabetes	0.87 _[0.82,0.92] (<i>p</i> =6.3×10 ⁻⁶)	0.92 _[0.87,0.97] (<i>p</i> =0.002)	0.68 _[0.64,0.73] (<i>p</i> =1.8×10 ⁻²⁵)	1.01 _[0.95,1.07] (<i>p</i> =0.808)	
Stroke	1.01 _[0.90,1.14] (<i>p</i> =0.873)	0.86 _[0.78,0.96] (<i>p</i> =0.005)	0.93 _[0.82,1.07] (<i>p</i> =0.313)	0.84 _[0.75,0.95] (<i>p</i> =0.005)	
Asthma	0.92 _[0.88,0.96] (<i>p</i> =3.7×10 ⁻⁴)	1.06 _[1.02,1.11] (<i>p</i> =0.003)	0.93 _[0.89,0.98] (<i>p</i> =0.004)	1.07 _[1.02,1.11] (<i>p</i> =0.003)	
COPD	0.77 _[0.64,0.92] (<i>p</i> =0.004)	0.87 _[0.76,1.00] (<i>p</i> =0.056)	0.73 _[0.60,0.89] (<i>p</i> =0.001)	1.07 _[0.92,1.25] (<i>p</i> =0.382)	
Bronchitis	0.90 _[0.81,1.00] (<i>p</i> =0.050)	0.87 _[0.80,0.94] (<i>p</i> =7.9×10 ⁻⁴)	0.77 _[0.69,0.86] (<i>p</i> =7.6×10 ⁻⁶)	1.00 _[0.91,1.10] (<i>p</i> =0.969)	
Parkinson's	1.17 _[0.90,1.50] (<i>p</i> =0.234)	1.10 _[0.83,1.45] (<i>p</i> =0.507)	1.16 _[0.88,1.54] (<i>p</i> =0.284)	1.51 _[1.16,1.95] (<i>p</i> =0.002)	
Dementia	0.77 _[0.40,1.47] (<i>p</i> =0.422)	0.80 _[0.50,1.27] (<i>p</i> =0.341)	0.65 _[0.32,1.32] (<i>p</i> =0.231)	1.03 _[0.59,1.78] (<i>p</i> =0.920)	
Depression	0.94 _[0.89,0.99] (<i>p</i> =0.019)	0.99 _[0.95,1.04] (<i>p</i> =0.795)	0.92 _[0.87,0.97] (<i>p</i> =0.002)	0.99 _[0.95,1.04] (<i>p</i> =0.801)	
	AAo max area per 188.4 mm ²	AAo distensibility per 1.4 × 10 ⁻³ mmHg ⁻¹	DAo max area per 97.8 mm ²	DAo distensibility per 1.6 × 10 ⁻³ mmHg ⁻¹	
Hypertension	1.32 _[1.27,1.36] (<i>p</i> =4.6×10 ⁻⁵⁵)	0.74 _[0.70,0.78] (<i>p</i> =6.6×10 ⁻³⁰)	1.20 _[1.15,1.25] (<i>p</i> =1.3×10 ⁻¹⁹)	0.80 _[0.76,0.84] (<i>p</i> =6.6×10 ⁻²⁰)	
High cholesterol	0.98 _[0.94,1.02] (<i>p</i> =0.375)	0.92 _[0.87,0.98] (<i>p</i> =0.006)	0.90 _[0.85,0.94] (<i>p</i> =2.9×10 ⁻⁵)	0.94 _[0.89,0.99] (<i>p</i> =0.022)	
Cardiac disease	1.07 _[1.02,1.14] (<i>p</i> =0.012)	1.05 _[0.98,1.11] (<i>p</i> =0.164)	0.93 _[0.88,1.00] (<i>p</i> =0.036)	1.03 _[0.97,1.10] (<i>p</i> =0.332)	
PVD	0.63 _[0.39,1.03] (<i>p</i> =0.065)	1.03 _[0.64,1.66] (<i>p</i> =0.913)	0.95 _[0.59,1.52] (<i>p</i> =0.836)	1.24 _[0.95,1.63] (<i>p</i> =0.115)	
Diabetes	0.79 _[0.74,0.85] (<i>p</i> =1.8×10 ⁻¹⁰)	0.93 _[0.86,1.01] (<i>p</i> =0.080)	0.71 _[0.66,0.77] (<i>p</i> =3.7×10 ⁻¹⁷)	0.88 _[0.81,0.96] (<i>p</i> =0.005)	
Stroke	0.98 _[0.85,1.12] (<i>p</i> =0.764)	0.98 _[0.83,1.15] (<i>p</i> =0.762)	0.93 _[0.80,1.08] (<i>p</i> =0.334)	0.89 _[0.74,1.07] (<i>p</i> =0.201)	
Asthma	0.95 _[0.90,1.00] (<i>p</i> =0.038)	1.01 _[0.96,1.06] (<i>p</i> =0.724)	0.89 _[0.84,0.95] (<i>p</i> =1.2×10 ⁻⁴)	0.99 _[0.94,1.04] (<i>p</i> =0.600)	
COPD	0.92 _[0.76,1.10] (<i>p</i> =0.357)	1.04 _[0.85,1.27] (<i>p</i> =0.680)	0.87 _[0.71,1.07] (<i>p</i> =0.182)	1.10 _[0.93,1.31] (<i>p</i> =0.260)	
Bronchitis	0.88 _[0.79,0.98] (<i>p</i> =0.025)	0.96 _[0.85,1.08] (<i>p</i> =0.505)	0.94 _[0.83,1.06] (<i>p</i> =0.304)	0.99 _[0.88,1.10] (<i>p</i> =0.794)	
Parkinson's	1.00 _[0.71,1.42] (<i>p</i> =0.997)	0.88 _[0.53,1.46] (<i>p</i> =0.610)	0.94 _[0.64,1.39] (<i>p</i> =0.770)	1.04 _[0.71,1.52] (<i>p</i> =0.844)	
Dementia	1.02 _[0.55,1.91] (<i>p</i> =0.944)	0.58 _[0.18,1.91] (<i>p</i> =0.372)	1.09 _[0.55,2.16] (<i>p</i> =0.803)	0.58 _[0.18,1.87] (<i>p</i> =0.362)	
Depression	0.97 _[0.92,1.02] (<i>p</i> =0.221)	1.02 _[0.97,1.07] (<i>p</i> =0.519)	0.96 _[0.90,1.02] (<i>p</i> =0.195)	1.01 _[0.96,1.06] (<i>p</i> =0.614)	

Supplementary Table 10. Associations of cardiac and aortic imaging phenotypes with common diseases. The odds ratio of each imaging phenotype as a risk factor for a common disease as outcome is reported. Sex, age, weight and height were adjusted in logistic regression. n = 25,743 subjects were analysed with available disease information. The values are depicted as odds ratio [95% confidence interval] (two-sided t-test p-value).

Structure	$-\log_{10}(p)$	r	Imaging phenotype	Non-imaging phenotype	Field ID
LV	319.4	0.26	LVM	Systolic blood pressure	4080-2.0
	307.7	-0.33	LVEDV	Pulse rate	4194-2.0
	226.5	0.22	Wall thickness AHA 9	Diastolic blood pressure	4079-2.0
	160.8	0.17	LVEDV	Number of days/week of vigorous physical activity	904-2.0
	69.8	0.11	LVEDV	Number of days/week of moderate physical activity	884-2.0
RV	307.7	-0.33	RVEDV	Pulse rate	4194-2.0
	180.0	0.18	RVEDV	Number of days/week of vigorous physical activity	904-2.0
	133.3	0.17	RVEF	Systolic blood pressure	4080-2.0
	73.6	-0.11	RVEDV	Overall health rating	2178-2.0
	70.0	0.11	RVEDV	Number of days/week of moderate physical activity	884-2.0
LA	307.7	-0.25	LAV max	Pulse rate	4194-2.0
	83.8	0.12	LASV	Number of days/week of vigorous physical activity	904-2.0
	68.1	0.11	LASV	Systolic blood pressure	4080-0.0
	33.9	0.08	LASV	Number of days/week of moderate physical activity	884-2.0
	29.4	-0.07	LASV	Overall health rating	2178-2.0
RA	213.4	-0.20	RAV min	Pulse rate	4194-2.0
	82.0	0.12	RAV min	Number of days/week of vigorous physical activity	904-2.0
	45.4	0.10	RAEF	Systolic blood pressure	4080-2.0
	41.7	-0.12	RAV min	Types of physical activity in last 4 weeks	6164-0.2
	36.7	-0.08	RAV max	Overall health rating	2178-0.0
AAo	260.1	0.22	AAo min area	Diastolic blood pressure	4079-0.0
	128.5	-0.18	AAo distensibility	Systolic blood pressure	4080-2.0
	46.2	-0.11	AAo distensibility	Pulse rate	102-2.0
	45.1	0.12	AAo min area	Birth weight	20022-0.0
	37.5	0.08	AAo max area	Whole body fat mass	23100-0.0
DAo	167.6	0.19	DAo min area	Diastolic blood pressure	4079-2.0
	130.0	-0.18	DAo distensibility	Systolic blood pressure	4080-2.0
	82.0	-0.13	DAo max area	Pulse rate	102-0.1
	64.3	0.11	DAo max area	Whole body fat mass	23100-0.0
	60.5	0.10	DAo max area	Hip circumference	49-0.0

Supplementary Table 11. Five most significant PheWAS associations for each anatomical structure. Note that if a non-imaging phenotype has multiple associations with imaging phenotypes of the same anatomical structure, only the top association is shown. For example, systolic blood pressure is significantly associated with several LV imaging phenotypes, including LVM, LVEDV, LVSV etc, but only the top association (lowest p-value) is shown, which is (LVM, Systolic blood pressure). Columns 2 and 3 denote the negative logarithm of correlation p-value (two-sided t-test) and Pearson's correlation coefficient r . Field ID denotes the UK Biobank code for the non-imaging phenotype. $n = 26,893$ subjects were included in the analysis.

Structure	$-\log_{10}(p)$	r	Imaging phenotype	Non-imaging phenotype	Field ID
LV	13.4	0.05	Wall thickness Global	Risk taking	2040-2.0
	11.1	-0.04	LVEDV	Happiness	4526-2.0
	8.7	-0.04	LVEDV	Neuroticism score	20127-0.0
	8.3	-0.04	LVSV	Seen doctor (GP) for nerves, anxiety, tension or depression	2090-2.0
	7.5	-0.03	LVEDV	Ever depressed for a whole week	4598-2.0
RV	16.5	-0.06	RVEDV	Neuroticism score	20127-0.0
	13.6	0.05	RVESV	Risk taking	2040-2.0
	12.1	-0.05	RVEDV	Frequency of depressed mood in last 2 weeks	2050-0.0
	10.7	-0.04	RVEDV	Happiness	4526-2.0
	9.0	-0.04	RVEDV	Seen doctor (GP) for nerves, anxiety, tension or depression	2090-0.0
LA	10.5	-0.04	LAV max	Happiness	4526-2.0
	10.2	-0.04	LASV	Frequency of depressed mood in last 2 weeks	2050-2.0
	6.8	-0.04	LASV	Neuroticism score	20127-0.0
	6.4	-0.03	LASV	Seen a psychiatrist for nerves, anxiety, tension or depression	2100-2.0
	6.4	-0.03	LAEF	Risk taking	2040-2.0
RA	14.5	-0.05	RAEF	Risk taking	2040-2.0
	10.9	-0.05	RAV max	Neuroticism score	20127-0.0
	8.3	-0.04	RAV max	Frequency of depressed mood in last 2 weeks	2050-0.0
	6.7	-0.03	RAV max	Seen doctor (GP) for nerves, anxiety, tension or depression	2090-2.0
	5.1	-0.03	RASV	Seen a psychiatrist for nerves, anxiety, tension or depression	2100-0.0
AAo	4.6	0.03	AAo max area	Risk taking	2040-0.0
	2.9	0.04	AAo max area	Substances taken for depression	20546-0.1
	1.9	0.05	AAo max area	Substances taken for anxiety	20549-0.1
	1.6	0.03	AAo distensibility	Frequency of depressed mood in last 2 weeks	2050-1.0
	1.4	0.03	AAo distensibility	Ever depressed for a whole week	4598-1.0
DAo	5.4	-0.03	DAo max area	Happiness	4526-2.0
	5.3	0.03	DAo max area	Risk taking	2040-0.0
	1.9	-0.02	DAo min area	Ever depressed for a whole week	4598-2.0
	1.9	0.03	DAo max area	Substances taken for depression	20546-0.1
	1.9	-0.02	DAo max area	Frequency of depressed mood in last 2 weeks	2050-0.0

Supplementary Table 12. Five most significant PheWAS associations in the mental health category for each anatomical structure. Columns 2 and 3 denote the negative logarithm of correlation p-value (two-sided t-test) and Pearson's correlation coefficient r . $n = 26,893$ subjects were included in the analysis.

Structure	$-\log_{10}(p)$	r	Imaging phenotype	Non-imaging phenotype	Field ID
LV	8.7	-0.04	E_{cc} AHA 15	Time to answer	4288-2.0
	7.9	0.04	LVM	Fluid intelligence score	20016-2.0
	5.3	-0.04	E_{ll} 3	Time elapsed	4256-2.1
	5.0	-0.04	E_{ll} 3	Interval between previous point and current one in alphanumeric path	6773-2.8
	4.8	-0.04	E_{ll} 3	Time last key touched	4255-2.1
RV	28.8	0.07	RVESV	Fluid intelligence score	20016-2.0
	7.1	-0.03	RVEDV	Duration to first press of snap-button in each round	404-2.10
	6.5	-0.03	RVEDV	Mean time to correctly identify matches	20023-2.0
	6.4	0.04	RVESV	Number of puzzles correctly solved	6373-2.0
	5.5	0.03	RVEDV	FI3 : word interpolation	4957-2.0
LA	7.9	0.05	LAV min	Interval between previous point and current one in alphanumeric path	6773-2.11
	5.0	0.04	LAV min	Interval between previous point and current one in numeric path	6772-2.21
	4.7	0.04	LAV min	Duration to complete alphanumeric path	6350-2.0
	4.4	0.03	LAV min	Duration to first press of snap-button in each round	404-2.7
	4.3	0.03	LAV min	Time elapsed	4256-2.2
RA	18.8	0.06	RAV max	Fluid intelligence score	20016-2.0
	6.1	0.04	RAV min	Maximum digits remembered correctly	4282-2.0
	5.7	0.04	RAV min	Number of rounds of numeric memory test performed	4283-2.0
	4.5	0.04	RAV max	Value entered	6312-2.6
	4.2	0.04	RAV max	Number of puzzles correctly solved	6373-2.0
AAo	2.8	0.03	AAo max area	Total errors traversing alphanumeric path	6351-2.0
	2.5	0.03	AAo max area	Interval between previous point and current one in alphanumeric path	6773-2.0
	2.4	0.02	AAo max area	Time to complete round	400-2.3
	2.3	-0.03	AAo distensibility	Duration to first press of snap-button in each round	404-0.3
	2.2	0.02	AAo max area	Time last key touched	4255-2.0
DAo	5.2	0.04	DAo min area	Total errors traversing alphanumeric path	6351-2.0
	5.0	-0.04	DAo min area	Number of puzzles correctly solved	6373-2.0
	3.3	-0.03	DAo min area	Number of symbol digit matches made correctly	23324-2.0
	3.3	0.03	DAo max area	Interval between previous point and current one in alphanumeric path	6773-2.0
	3.1	0.02	DAo min area	Mean time to correctly identify matches	20023-0.0

Supplementary Table 13. Five most significant PheWAS associations in the cognitive function category for each anatomical structure. Columns 2 and 3 denote the negative logarithm of correlation p-value (two-sided t-test) and Pearson's correlation coefficient r . $n = 26,893$ subjects were included in the analysis.

	LVM (g)	LVEDV (mL)	LVEF (%)	RVEDV (mL)	RVEF (%)
Birth weight, per 0.6 kg	0.5 _[0.3,0.7] ($p=1.4 \times 10^{-5}$)	1.0 _[0.6,1.5] ($p=7.5 \times 10^{-7}$)	0.1 _[-0.0,0.2] ($p=0.090$)	1.8 _[1.3,2.2] ($p=7.4 \times 10^{-15}$)	-0.1 _[-0.2,-0.0] ($p=0.013$)
	LAV max (mL)	LAEF (%)	RAV max (mL)	RAEF (%)	
Birth weight, per 0.6 kg	-0.7 _[-1.0,-0.3] ($p=4.3 \times 10^{-4}$)	0.4 _[0.2,0.5] ($p=2.5 \times 10^{-6}$)	1.7 _[1.2,2.1] ($p=2.2 \times 10^{-14}$)	0.2 _[0.0,0.4] ($p=0.011$)	
	AAo max area (mm ²)	AAo distensibility	DAo max area (mm ²)	DAo distensibility	
Birth weight, per 0.6 kg	20.2 _[17.3,23.2] ($p=10^{-40}$)	-0.04 _[-0.1,-0.0] ($p=8.8 \times 10^{-4}$)	7.1 _[5.8,8.5] ($p=3.2 \times 10^{-26}$)	-0.1 _[-0.1,-0.0] ($p=5.5 \times 10^{-4}$)	

Supplementary Table 14. Associations of cardiac and aortic imaging phenotypes with birth weight. Sex, age, sex * age, weight, height, SBP, DBP, current smoking status, alcohol intake, vigorous PA frequency, high cholesterol and diabetes were adjusted in regression. $n = 12,169$ subjects were analysed with available information for all independent variables. The values are depicted as regression coefficient β [95% confidence interval] (two-sided t-test p-value).

	LVM (g)	LVEDV (mL)	LVEF (%)	RVEDV (mL)	RVEF (%)
Risk taking	1.0 _[0.6,1.4] (<i>p</i> =4.4×10 ⁻⁶)	0.02 _[-0.8,0.8] (<i>p</i> =0.962)	-0.3 _[-0.5,-0.1] (<i>p</i> =0.004)	0.2 _[-0.7,1.0] (<i>p</i> =0.724)	-0.5 _[-0.7,-0.3] (<i>p</i> =1.6×10 ⁻⁷)
Neuroticism score, per 3.2	-0.03 _[-0.2,0.2] (<i>p</i> =0.744)	-0.6 _[-0.9,-0.2] (<i>p</i> =0.002)	0.1 _[-0.0,0.2] (<i>p</i> =0.129)	-1.0 _[-1.3,-0.6] (<i>p</i> =9.8×10 ⁻⁷)	0.1 _[0.0,0.2] (<i>p</i> =0.019)
	LAV max (mL)	LAEF (%)	RAV max (mL)	RAEF (%)	
Risk taking	-0.3 _[-1.0,0.5] (<i>p</i> =0.489)	-0.5 _[-0.8,-0.2] (<i>p</i> =0.001)	0.8 _[-0.0,1.6] (<i>p</i> =0.063)	-0.8 _[-1.1,-0.5] (<i>p</i> =5.3×10 ⁻⁷)	
Neuroticism score, per 3.2	-0.4 _[-0.7,-0.1] (<i>p</i> =0.023)	-0.04 _[-0.2,0.1] (<i>p</i> =0.585)	-0.7 _[-1.0,-0.3] (<i>p</i> =3.7×10 ⁻⁴)	0.05 _[-0.1,0.2] (<i>p</i> =0.477)	
	AAo max area (mm ²)	AAo distensibility	DAo max area (mm ²)	DAo distensibility	
Risk taking	5.4 _[-0.3,11.1] (<i>p</i> =0.064)	-0.01 _[-0.1,0.0] (<i>p</i> =0.553)	1.5 _[-1.0,4.1] (<i>p</i> =0.242)	0.02 _[-0.0,0.1] (<i>p</i> =0.462)	
Neuroticism score, per 3.2	1.1 _[-1.4,3.7] (<i>p</i> =0.380)	-0.01 _[-0.0,0.0] (<i>p</i> =0.391)	-0.3 _[-1.5,0.8] (<i>p</i> =0.572)	-0.01 _[-0.0,0.0] (<i>p</i> =0.658)	

Supplementary Table 15. Associations of cardiac and aortic imaging phenotypes with mental health measures. Sex, age, sex * age, weight, height, SBP, DBP, current smoking status, alcohol intake, vigorous PA frequency, high cholesterol and diabetes were adjusted in regression. *n* = 16,568 subjects were analysed with available information for all independent variables. The values are depicted as regression coefficient β [95% confidence interval] (two-sided t-test *p*-value). Risk taking is a binary variable, with 0 denoting no and 1 denoting yes. Neuroticism score ranges from 0 to 12.

	LVM (g)	LVEDV (mL)	LVEF (%)	RVEDV (mL)	RVEF (%)
Fluid intelligence, per 2.1	0.8 _[0.6,0.9] (<i>p</i> =1.8×10 ⁻¹⁸)	1.1 _[0.7,1.4] (<i>p</i> =3.3×10 ⁻¹⁰)	-0.1 _[-0.2,-0.0] (<i>p</i> =0.033)	2.0 _[1.6,2.3] (<i>p</i> =2×10 ⁻²⁶)	-0.3 _[-0.3,-0.2] (<i>p</i> =3.9×10 ⁻¹⁰)
	LAV max (mL)	LAEF (%)	RAV max (mL)	RAEF (%)	
Fluid intelligence, per 2.1	0.1 _[-0.2,0.4] (<i>p</i> =0.553)	-0.01 _[-0.1,0.1] (<i>p</i> =0.879)	1.6 _[1.3,2.0] (<i>p</i> =1.9×10 ⁻²⁰)	-0.2 _[-0.3,-0.0] (<i>p</i> =0.013)	
	AAo max area (mm ²)	AAo distensibility	DAo max area (mm ²)	DAo distensibility	
Fluid intelligence, per 2.1	3.1 _[0.7,5.4] (<i>p</i> =0.012)	-0.01 _[-0.0,0.0] (<i>p</i> =0.194)	0.7 _[-0.4,1.8] (<i>p</i> =0.208)	0.00 _[-0.0,0.0] (<i>p</i> =0.926)	

Supplementary Table 16. Associations of cardiac and aortic imaging phenotypes with fluid intelligence score. Sex, age, sex * age, weight, height, SBP, DBP, current smoking status, alcohol intake, vigorous PA frequency, high cholesterol and diabetes are adjusted in regression. *n* = 18,369 subjects were analysed with available information for all independent variables. The values are depicted as regression coefficient β [95% confidence interval] (two-sided t-test *p*-value). Fluid intelligence score ranges from 0 to 13.

Risk factor	Data source	Cohorts
SBP	Evangelou et al, 2018 ⁷³	UK Biobank (<i>n</i> = 458,577) + ICBP (<i>n</i> = 299,024) + MVP (<i>n</i> = 220,520) + EGCUT (<i>n</i> = 28,742)
Diabetes	Morris et al, 2012 ⁷⁴	DIAGRAM (<i>n</i> = 12,171 cases, <i>n</i> = 56,862 controls)
Birth weight	Warrington et al, 2019 ⁷⁵	EGG (<i>n</i> = 80,745) + UK Biobank (<i>n</i> = 217,397)
Risk tolerance	Linner et al, 2019 ⁷⁶	UK Biobank (<i>n</i> = 431,126) + 10 replication cohorts (<i>n</i> = 35,445)
Fluid intelligence	Davies et al, 2011 ⁷⁷	CAGES (<i>n</i> = 3,511)

Supplementary Table 17. Data sources for the genetic associations of risk factors of interest. ICBP: International Consortium of Blood Pressure Genome Wide Association Studies; MVP: Million Veteran Program; EGCUT, Estonian Genome Center, University of Tartu; DIAGRAM: DIABetes Genetics Replication and Meta-analysis; EGG: Early Growth Genetics; CAGES: Cognitive Ageing Genetics in England and Scotland.

	Risk factor	Observational analysis	Mendelian randomisation		
			IVW	WM	MR-Egger
LVM (g)	SBP, per 18.0 mmHg	4.8 _[4.6,5.1] ($p=10^{-324}$)	4.8 _[1.4,8.2] ($p=0.006$)	4.6 _[0.1,9.0] ($p=0.044$)	11.7 _[-1.5,24.9] ($p=0.085$)
	Diabetes	-1.0 _[-1.8,-0.1] ($p=0.025$)	-0.3 _[-1.2,0.6] ($p=0.499$)	-0.3 _[-1.3,0.7] ($p=0.539$)	-0.02 _[-5.4,5.3] ($p=0.995$)
	Birth weight, per 0.6 kg	0.5 _[0.3,0.7] ($p=1.4\times 10^{-5}$)	1.2 _[0.5,1.9] ($p=0.001$)	1.0 _[0.0,2.1] ($p=0.049$)	1.8 _[-0.2,3.7] ($p=0.078$)
	Risk taking	1.0 _[0.6,1.4] ($p=4.4\times 10^{-6}$)	2.4 _[-1.5,6.3] ($p=0.233$)	3.8 _[-2.0,9.5] ($p=0.196$)	11.1 _[-5.3,27.5] ($p=0.196$)
	Fluid intelligence, per 2.1	0.8 _[0.6,0.9] ($p=1.8\times 10^{-18}$)	0.1 _[-1.1,1.4] ($p=0.825$)	0.2 _[-1.4,1.8] ($p=0.820$)	-1.6 _[-7.3,4.2] ($p=0.601$)
LVEDV (mL)	SBP, per 18.0 mmHg	5.8 _[5.3,6.3] ($p=2.4\times 10^{-130}$)	0.8 _[-4.8,6.5] ($p=0.771$)	-3.5 _[-11.0,3.9] ($p=0.355$)	-5.5 _[-27.1,16.1] ($p=0.617$)
	Diabetes	-8.7 _[-10.3,-7.0] ($p=1.4\times 10^{-24}$)	-0.7 _[-2.1,0.8] ($p=0.382$)	-0.9 _[-2.5,0.8] ($p=0.311$)	-2.4 _[-11.3,6.5] ($p=0.615$)
	Birth weight, per 0.6 kg	1.0 _[0.6,1.5] ($p=7.5\times 10^{-7}$)	2.4 _[1.1,3.6] ($p=1.5\times 10^{-4}$)	1.9 _[0.2,3.6] ($p=0.031$)	3.0 _[-0.3,6.4] ($p=0.079$)
	Risk taking	0.02 _[-0.8,0.8] ($p=0.962$)	1.2 _[-5.5,7.9] ($p=0.725$)	3.8 _[-6.1,13.8] ($p=0.452$)	14.3 _[-13.9,42.6] ($p=0.328$)
	Fluid intelligence, per 2.1	1.1 _[0.7,1.4] ($p=3.3\times 10^{-10}$)	0.3 _[-1.8,2.4] ($p=0.769$)	0.3 _[-2.5,3.2] ($p=0.816$)	-1.3 _[-11.2,8.6] ($p=0.806$)
LVEF (%)	SBP, per 18.0 mmHg	0.9 _[0.8,1.0] ($p=4.9\times 10^{-49}$)	0.2 _[-1.1,1.5] ($p=0.757$)	0.4 _[-1.3,2.1] ($p=0.665$)	2.6 _[-2.4,7.7] ($p=0.309$)
	Diabetes	-1.0 _[-1.4,-0.5] ($p=5.1\times 10^{-6}$)	-0.2 _[-0.5,0.1] ($p=0.165$)	-0.3 _[-0.6,0.1] ($p=0.116$)	-0.8 _[-2.3,0.7] ($p=0.342$)
	Birth weight, per 0.6 kg	0.1 _[-0.0,0.2] ($p=0.090$)	0.2 _[-0.0,0.5] ($p=0.080$)	0.2 _[-0.2,0.6] ($p=0.258$)	-0.1 _[-0.8,0.7] ($p=0.863$)
	Risk taking	-0.3 _[-0.5,-0.1] ($p=0.004$)	0.5 _[-1.3,2.2] ($p=0.618$)	0.4 _[-2.1,2.8] ($p=0.773$)	0.9 _[-6.7,8.4] ($p=0.827$)
	Fluid intelligence, per 2.1	-0.1 _[-0.2,-0.0] ($p=0.033$)	0.2 _[-0.3,0.7] ($p=0.364$)	0.2 _[-0.5,0.8] ($p=0.575$)	1.3 _[-1.0,3.6] ($p=0.288$)
RVEDV (mL)	SBP, per 18.0 mmHg	3.0 _[2.5,3.5] ($p=4.8\times 10^{-32}$)	0.04 _[-5.8,5.9] ($p=0.988$)	0.4 _[-7.5,8.4] ($p=0.916$)	9.0 _[-13.6,31.5] ($p=0.439$)
	Diabetes	-11.1 _[-12.9,-9.3] ($p=3.4\times 10^{-34}$)	-1.6 _[-3.0,-0.3] ($p=0.016$)	-1.8 _[-3.5,-0.1] ($p=0.036$)	2.3 _[-4.9,9.5] ($p=0.549$)
	Birth weight, per 0.6 kg	1.8 _[1.3,2.2] ($p=7.4\times 10^{-15}$)	3.2 _[1.8,4.5] ($p=3.2\times 10^{-6}$)	2.8 _[1.0,4.6] ($p=0.002$)	4.3 _[0.6,7.9] ($p=0.023$)
	Risk taking	0.2 _[-0.7,1.0] ($p=0.724$)	3.1 _[-4.3,10.6] ($p=0.407$)	-0.5 _[-10.8,9.8] ($p=0.919$)	15.2 _[-16.2,46.5] ($p=0.350$)
	Fluid intelligence, per 2.1	2.0 _[1.6,2.3] ($p=2\times 10^{-26}$)	0.1 _[-2.0,2.3] ($p=0.894$)	0.4 _[-2.7,3.5] ($p=0.811$)	-2.3 _[-12.9,8.2] ($p=0.675$)
RVEF (%)	SBP, per 18.0 mmHg	1.6 _[1.5,1.7] ($p=1.4\times 10^{-161}$)	0.9 _[-0.5,2.2] ($p=0.222$)	-0.3 _[-2.0,1.4] ($p=0.742$)	0.4 _[-4.8,5.7] ($p=0.877$)
	Diabetes	-0.7 _[-1.1,-0.3] ($p=5\times 10^{-4}$)	-0.1 _[-0.5,0.2] ($p=0.543$)	0.04 _[-0.3,0.4] ($p=0.850$)	-0.5 _[-2.7,1.6] ($p=0.629$)
	Birth weight, per 0.6 kg	-0.1 _[-0.2,-0.0] ($p=0.013$)	-0.1 _[-0.4,0.2] ($p=0.458$)	-0.1 _[-0.4,0.3] ($p=0.790$)	-0.7 _[-1.5,0.1] ($p=0.070$)
	Risk taking	-0.5 _[-0.7,-0.3] ($p=1.6\times 10^{-7}$)	-0.1 _[-1.6,1.5] ($p=0.946$)	0.2 _[-2.1,2.5] ($p=0.883$)	0.1 _[-6.5,6.6] ($p=0.979$)
	Fluid intelligence, per 2.1	-0.3 _[-0.3,-0.2] ($p=3.9\times 10^{-10}$)	0.1 _[-0.3,0.6] ($p=0.581$)	0.2 _[-0.5,0.9] ($p=0.611$)	2.3 _[0.0,4.6] ($p=0.063$)
AAo max area (mm ²)	SBP, per 18.0 mmHg	-13.5 _[-16.8,-10.2] ($p=1.2\times 10^{-15}$)	32.3 _[-5.4,69.9] ($p=0.093$)	49.3 _[-4.4,103.0] ($p=0.072$)	60.3 _[-83.8,204.3] ($p=0.415$)
	Diabetes	-19.7 _[-31.5,-7.9] ($p=0.001$)	-12.0 _[-20.0,-4.0] ($p=0.003$)	-10.2 _[-20.5,0.1] ($p=0.051$)	-19.1 _[-64.0,25.8] ($p=0.429$)
	Birth weight, per 0.6 kg	20.2 _[17.3,23.2] ($p=10^{-40}$)	25.1 _[16.0,34.2] ($p=6.2\times 10^{-8}$)	19.5 _[7.6,31.5] ($p=0.001$)	14.9 _[-10.2,39.9] ($p=0.246$)
	Risk taking	5.4 _[-0.3,11.1] ($p=0.064$)	15.2 _[-39.1,69.5] ($p=0.582$)	24.9 _[-48.4,98.2] ($p=0.505$)	152.2 _[-71.9,376.4] ($p=0.194$)
	Fluid intelligence, per 2.1	3.1 _[0.7,5.4] ($p=0.012$)	3.0 _[-13.9,20.0] ($p=0.724$)	6.5 _[-14.1,27.1] ($p=0.538$)	-17.8 _[-99.7,64.1] ($p=0.676$)
AAo distensibility	SBP, per 18.0 mmHg	-0.2 _[-0.2,-0.2] ($p=1.1\times 10^{-41}$)	-0.3 _[-0.6,-0.0] ($p=0.042$)	-0.4 _[-0.8,-0.0] ($p=0.048$)	-1.0 _[-2.1,0.0] ($p=0.062$)
	Diabetes	0.00 _[-0.1,0.1] ($p=0.991$)	-0.1 _[-0.2,-0.0] ($p=0.001$)	-0.1 _[-0.2,-0.0] ($p=0.014$)	-0.2 _[-0.5,0.1] ($p=0.297$)
	Birth weight, per 0.6 kg	-0.04 _[-0.1,-0.0] ($p=8.8\times 10^{-4}$)	-0.03 _[-0.1,0.0] ($p=0.269$)	0.01 _[-0.1,0.1] ($p=0.898$)	0.1 _[-0.0,0.3] ($p=0.058$)
	Risk taking	-0.01 _[-0.1,0.0] ($p=0.553$)	0.1 _[-0.3,0.5] ($p=0.591$)	-0.2 _[-0.7,0.3] ($p=0.439$)	-0.00 _[-1.5,1.5] ($p=0.995$)
	Fluid intelligence, per 2.1	-0.01 _[-0.0,0.0] ($p=0.194$)	-0.1 _[-0.2,0.1] ($p=0.449$)	-0.03 _[-0.2,0.1] ($p=0.756$)	0.2 _[-0.4,0.9] ($p=0.490$)

Supplementary Table 18. Effects of risk factors on cardiac and aortic imaging phenotypes by Mendelian randomisation analysis, compared to observational analysis. For Mendelian randomisation, three methods were used, including inverse-variance weighting (IVW), weighted median (WM) and MR-Egger. Sex, age, height and genetic principal components were adjusted. $n = 22,229$ subjects were analysed with available genetic information. Observational analysis results come from previously reported tables in this paper. The values are depicted as regression coefficient β [95% confidence interval] (two-sided t-test p-value). The Bonferroni threshold for multiple comparison (5 risk factors and 7 imaging phenotypes) is $p_{Bonf} = 1.4 \times 10^{-3}$ for $\alpha = 0.05$.